- 1 Isoform-level transcriptome-wide association uncovers extensive novel genetic risk mechanisms
- 2 for neuropsychiatric disorders in the human brain
- 4 AUTHORS

7

8

- 5 Arjun Bhattacharya^{1,2}, Daniel D. Vo^{3,4}, Connor Jops^{3,4}, Minsoo Kim^{5,6}, Cindy Wen⁵, Jonatan L. Hervoso⁷,
- 6 Bogdan Pasaniuc^{1,6,8±}, Michael J. Gandal^{3,4,5,6±}

AFFILIATIONS

- 9 1. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of
- 10 California, Los Angeles, California, USA
- 11 2. Institute for Quantitative and Computational Biosciences, David Geffen School of Medicine, University
- of California, Los Angeles, California, USA
- 13 3. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
- 14 Pennsylvania, USA
- 15 4. Lifespan Brain Institute at Penn Med and the Children's Hospital of Philadelphia, Philadelphia,
- 16 Pennsylvania, USA
- 17 5. Department of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of
- 18 Medicine, University of California, Los Angeles, California, USA
- 19 6. Department of Human Genetics, David Geffen School of Medicine, University of California, Los
- 20 Angeles, CA, USA
- 21 7. Bioinformatics Interdepartmental Program, University of California, Los Angeles, CA, USA
- 22 8. Department of Computational Medicine, David Geffen School of Medicine, University of California,
- 23 Los Angeles, CA, USA
- 24 *Equal contribution

25

26

28

CORRESPONDENCE

27 Corresponding author: Arjun Bhattacharya (abtbhatt@ucla.edu)

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

ABSTRACT Integrative methods, like colocalization and transcriptome-wide association studies (TWAS), identify transcriptomic mechanisms at only a fraction of trait-associated genetic loci from genome-wide association studies (GWAS). Here, we show that a reliance on reference functional genomics panels of only total gene expression greatly contributes to this reduced discovery. This is particularly relevant for neuropsychiatric traits, as the brain expresses extensive, complex, and unique alternative splicing patterns giving rise to multiple genetically-regulated transcript-isoforms per gene. Integrating highly correlated transcript-isoform expression with GWAS requires methodological innovations. We introduce isoTWAS, a multivariate framework to integrate genetics, isoform-level expression, and phenotypic associations in a step-wise testing framework, and evaluate it using data from the Genotype-Tissue Expression (GTEx) Project, PsychENCODE Consortium, and other sources. isoTWAS shows three main advantages. First, joint, multivariate modeling of isoform expression from cis-window SNPs improves prediction by ~1.8-2.4 fold, compared to univariate modeling. Second, compared to gene-level TWAS, these improvements in prediction lead to ~1.9-2.5-fold increase in the number of testable genes and a median of 25-70% increase in cross-validated prediction of total gene expression, with the added ability to jointly capture expression and splicing mechanisms. In external validation, isoform-centric models predicted gene expression at percent variance explained >1% for 50% more genes than genecentric models. Third, across 15 neuropsychiatric traits, isoTWAS increased discovery of trait associations within GWAS loci over TWAS, capturing ~60% more unique loci and 95% of loci detected by TWAS. Results from extensive simulations showed no increase in false discovery rate and reinforce isoTWAS's advantages in prediction and trait mapping power over TWAS, especially when genetic effects on expression vary across isoforms of the same gene. We illustrate multiple biologically-relevant isoTWAS-identified trait associations undetectable by gene-level methods, including isoforms of AKT3, CUL3, and HSPD1 with schizophrenia risk, and PCLO with multiple disorders. The isoTWAS framework addresses an unmet need to consider the transcriptome on the transcriptisoform level to increase discovery of trait associations, especially for brain-relevant traits.

INTRODUCTION

Over the past decade, the number of genetic associations with complex traits identified by genome-wide association studies (GWAS) has increased considerably^{1,2}. However, the slow translation of these genetic associations into concrete molecular mechanisms remains a major obstacle. As GWAS associations predominately localize within non-coding regions of the genome and are often tagged within large blocks of linkage disequilibrium (LD), the first major challenge is prioritizing the underlying causal variant(s) within a given locus and identifying their functional impact on nearby target genes. To address this, numerous methods have been developed to integrate transcriptomic reference panels with GWAS to prioritize genes at trait-associated loci^{3–15}. TWAS and related approaches (e.g., PrediXcan) impute the *cis*-component of gene expression predicted by germline genetics into an association cohort, thereby reducing multiple comparisons and increasing interpretability by identifying a set of genes at a locus that may underlie the genetic association^{3,4}. Despite these methodological advances, a majority of GWAS loci still lack robust mechanistic interpretation¹⁶.

Previous integrative analyses have largely focused on aggregated measurements of total gene expression but have not systematically explored the potentially large number of distinct transcriptiosoforms that can be generated from a given genetic locus through alternative splicing. Alternative splicing is a fundamental form of tissue-specific gene regulation present in more than 90% of human genes, that vastly expands the coding and regulatory potential of the genome 17-20; GENCODE v40 annotates an average of 4 isoforms per gene (mean 4.05, standard deviation 7.28, median 1)²¹. Genes uniquely expressed in the brain, which are longer and contain far more exons, undergo the greatest degree of splicing compared with other tissues and species—a mechanism contributing to the vast proteomic, phenotypic, and evolutionary complexity of the human brain^{22–25}. Some genes are known to express up to hundreds to thousands of unique isoforms in the human brain²⁵. Independent of gene expression, splicing dysregulation has been increasingly implicated as a putative disease mechanism^{24,26–30} including for neuropsychiatric disorders^{10,24,27,31}. Yet, local splicing events can be computationally intensive to measure and are difficult to systematically integrate across multiple distinct large-scale datasets. Splicing is often coordinated across a gene, yielding many non-independent features that increases multiple testing

burden. In contrast, transcript-isoform abundance can now be rapidly estimated across large-scale RNAseq datasets using pseudoalignment methods^{32,33}. Furthermore, in the brain, isoform-level expression changes have shown greater enrichment for schizophrenia heritability than gene or local splicing changes^{22,31,34–36}. However, to fully integrate transcript-isoform quantifications with GWAS, innovative computational methods are needed that jointly model the highly correlated transcripts of the same gene. Here, we present isoform-level TWAS (isoTWAS), a flexible and scalable approach for complex trait mapping by integrating genetic effects on isoform-level expression with GWAS. In extensive simulations and real data applications in the Genotype-Tissue Expression (GTEx) Project³⁷ and the PsychENCODE Consortium^{22,24}, we show that isoTWAS provides several important advantages to trait mapping. First, in the transcriptomic prediction step, the correlation between isoforms provides additional information that is unavailable when only gene-level expression is measured, which can be leveraged to improve prediction³⁸ accuracy of individual isoforms in >80% of cases by a median of ~1.8-2.4-fold improvement and of total gene expression by 25-70%. In parallel, our isoform-centric framework uncovers crossvalidated predictive models for ~2-fold more genes, doubling the number of testable features in the trait mapping step. Third, divergent patterns of genetic effects across isoforms can be leveraged to provide a more granular hypothesis for a mechanism underlying the SNP-trait relationship. Finally, the isoTWAS framework jointly captures expression and splicing disease mechanisms, while maintaining a wellcontrolled false discovery rate. Altogether, using GWAS data for 15 neuropsychiatric traits, isoTWAS greatly increases the power to detect gene-level trait associations uncovering associations at ~60% more GWAS loci compared to traditional gene-level TWAS. These results stress the need to shift focus to transcript-isoforms to increase discovery of transcriptomic mechanisms underlying genetic associations with complex traits.

RESULTS

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

The isoTWAS framework

isoTWAS seeks to prioritize genes with transcript-isoforms of genes whose *cis*-genetic component of expression is significantly associated with a complex trait. We extend the traditional gene-level TWAS

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

approach by jointly modeling the expression of distinct transcript-isoforms of a given gene as a matrix while accounting for the pair-wise correlations between these isoforms^{21,37,39,40}. Here, we assume that local genetic variants directly modulate expression of an isoform. In addition, we assume that the abundance of a gene is measured as the is the sum of the abundance of its isoforms, computed as transcripts per million, or TPM (Supplemental Figure S1)^{32,33,41,42}. Flexibly integrating isoform-level expression into trait mapping may lead to novel discoveries in disease mapping and prioritize specific isoforms that explain genetic associations. Accordingly, gene-level trait mapping using traditional TWAS methods may not necessarily detect a trait association on the gene-level if a gene has multiple isoforms but only one is associated with the trait (Figure 1a). This scenario may be particularly relevant in the human brain, where some genes may express up to hundreds to thousands of unique isoforms²⁵. By modeling the genetic architectures of isoforms of a gene simultaneously, isoTWAS provides a deeper understanding of potential transcriptomic mechanisms that underlie genetic associations. The isoTWAS framework contains three general steps (Figure 1). First, we build multivariate predictive models of isoform-level expression using well-powered functional genomics training datasets, including GTEx³⁷ and PsychENCODE^{24,27}. Here, we trained and systematically compared 4 multivariate predictive frameworks: (1) multivariate elastic net penalized regression⁴³, (2) multivariate LASSO penalized regression with simultaneous covariance estimation (MRCE)⁴⁴, (3) multivariate elastic net regression with stacked generalization (joinet)⁴⁵, and (4) sparse partial least squares (SPLS)⁴⁶. As a baseline for comparison, we also modeled each individual isoform independently with univariate regularized regressions, as implemented in Gusev et al's FUSION software^{4,43,47,48} (see Methods and Supplemental **Methods**). Models were trained to predict isoform expression using the set of *cis*-SNPs within 1 Megabase (Mb) of the gene body (Methods, Figure 1b). Model performance was assessed via 5-fold cross-validation, using McNemar's adjusted R² between observed and predicted expression. Next, we use these models to impute isoform expression into an external GWAS cohort and quantify the association with the target GWAS phenotype (Figure 1b). If individual-level genotypes are available, isoform expression can be directly imputed as a linear combination of the SNPs in the models, and these

associations can be estimated through appropriate regression analyses. If only GWAS summary statistics are available, imputation and association testing is conducted simultaneously through a weighted burden test⁴. Finally, isoTWAS performs step-wise hypothesis testing procedure to account for multiple comparisons and control for local LD structure. Isoform-level P-value are first aggregated to the gene-level to prioritize a gene using the Aggregated Cauchy Association Test (ACAT)⁴⁹, where false discovery rates are controlled, and then individual isoforms of prioritized genes are subjected to post-hoc family-wise error control⁵⁰ (**Supplemental Figure S2**, **Methods**). After this step, a set of isoforms are identified whose *cis*-genetic component of expression are associated with the trait of interest⁴. For these isoforms, we apply a rigorous permutation test whereby the SNP-to-isoform effects are permuted 10,000 times to generate a null distribution; this permutation test assesses how much signal is added by isoform expression, given the GWAS architecture of the locus, and controls for large LD blocks⁴. Lastly, we can isoform-level Bayesian fine-mapping at each locus with a significant trait association to identify the minimal credible set of isoforms that contains the 'casual' isoform at a 90% confidence level and to assign individual posterior inclusion probabilities (**Figure 1b**, **Methods**). isoTWAS is available as an R package through Github (https://github.com/bhattacharya-a-bt/isotwas).

Previous work has demonstrated that isoform and gene expression in simulations and real data.

Previous work has demonstrated that isoform-level quantifications, when propagated to the gene-level, can lead to more accurate gene expression estimates and differential expression results with short read RNA-seq data^{41,42}. We therefore hypothesized that our multivariate SNP-based imputation of isoform expression, when summed to the gene-level, would outperform traditional gene-level TWAS models. To systematically evaluate the performance of TWAS versus isoTWAS models on prediction of total gene expression across a variety of genetic architectures, we conducted an extensive set of simulations across 22 different gene loci using European-ancestry data from the 1000 Genomes Project⁵¹ (Methods, Figure 2a). At each gene locus, we controlled gene expression heritability and simulated 2-10 distinct isoforms, varying the proportion of causal isoQTLs (p_{causal}) and their sharing between isoforms (p_{shared}). We then trained cross-validated, multivariate predictive models of isoform expression (isoTWAS) or univariate models of gene expression (TWAS). For isoTWAS, of the specific multivariate prediction models tested,

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

multivariate elastic net⁴³ demonstrated the greatest CV prediction of isoform expression across most simulation settings (Figure 2b, Supplemental Figure S3, Supplemental Data 1). For gene expression prediction, the optimal isoTWAS models (in sum) outperformed the optimal TWAS model, particularly at sparser isoQTL architectures, with median absolute increase in adjusted R² of 0.6-3.5% (Figure 2c, Supplemental Figure S4, Supplemental Data 2). Performance gains decreased somewhat with denser isoQTL architectures, although real data is consistent with 0.1-1% sparsity (i.e., 1-10 causal e- and isoQTLs per gene or isoform)³⁷. In simulations, we found that isoTWAS prediction of gene expression also increases as the proportion of shared non-zero effect SNPs across isoforms decreases (Figure 2bc, Supplemental Figure S4, Supplemental Data 2). Next, we assessed predictive performance in real data from 48 tissues (13 brain) with sufficient sample sizes (N > 100) in GTEx for all genes with multiple expressed isoforms (Supplemental Table S1; **Methods**). Altogether, for 48 tissues in GTEx, we built significant predictive models for 50,000 to 80,000 isoforms across 8,000 to 12,000 unique genes per tissue (Supplemental Figure S11, Supplemental Table S2). We considered 3 main criteria to evaluate the performance of both the multivariate and isoform-centric approaches of isoTWAS: (1) the number of isoforms whose expression can be imputed using multivariate/univariate models with cross-validation (CV) R² > 0.01; (2) the number of unique genes with at least one isoform that can be imputed at CV R² > 0.01; and (3) the number of unique genes in which total gene expression can be imputed at CV R² > 0.01 using isoTWAS (summed) or TWAS models. At the isoform level (criterion 1), through joint multivariate modeling of isoform expression, we trained 2.3-2.5-fold more models at cross-validation (CV) R² > 0.01 across the 48 tissues, compared to traditional univariate approaches (Figure 3a, Supplemental Figure S5). Using these multivariate models, we improve prediction for 79-82% of isoforms with a median increase of ~1.8-2.4 fold increase in adjusted R² (Supplemental Figure S6, Supplemental Table S2). Concordant with simulations, we found that the multivariate elastic net overwhelmingly outperformed other multivariate (and univariate) methods, indicating that leveraging the shared genetic architecture between isoforms of the same gene greatly aids in prediction of each individual isoform (Supplemental Figure S7, Supplemental Table S2). Notably, we

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

observed that multivariate models were particularly important for brain tissues compared with non-brain tissues in GTEx, which showed significantly improved performance compared with univariate models (Figure 3b: P = 0.011 from OLS regression of median percent increase in CV R² for multivariate/univariate models against tissue type, adjusted for sample size), suggesting more shared isoQTL architecture in brain tissues than others which can be leveraged by isoTWAS for improved prediction. These gains in prediction accuracy directly translate into increased power in the trait association step⁵². At the gene level (criteria 2 and 3), isoTWAS also increased the number of genes with testable models in the trait mapping step and improved prediction of total gene expression. The number of unique genes with at least 1 isoTWAS model at CV R² > 0.01 (inclusion criterion for isoTWAS trait mapping) was 1.9-2.5 times larger than the number of unique genes with TWAS models achieving CV R² > 0.01 for gene expression prediction (Figure 3c, Supplemental Figure S8, Supplemental Table S2). For a given gene, isoTWAS models (summed) outperformed TWAS models in prediction of total gene expression by a median of 25-70% in cross validation (Supplemental Figure S9) with a 50-80% increase in the number of genes that are predicted at CV R² > 0.01 (Figure 3d, Supplemental Figure S10). We replicated these gains in total gene expression prediction using an independent, out of sample QTL reference panel of adult cortex from PsychENCODE/AMP-AD (Methods). Multivariate isoTWAS models outperformed univariate TWAS models in predicting total gene expression with a 15.2% median percent increase in adjusted R² when training in GTEx and testing in PsychENCODE/AMP-AD, and 23.9% vice versa: Figure 3e, Supplemental Table S3). As predictive performance is positively related to power to detect trait associations⁵¹, both the increased number and accuracy of trainable imputation models using isoTWAS's multivariate predictive framework have strong implications on increased discovery in trait mapping⁵¹. Performance of isoTWAS across distinct genomic contexts As genes can differ widely with respect to the number and expression patterns of their constituent isoforms, as well as by other potentially relevant features such as gene length and SNP density, we next

sought to characterize the impact of these factors of isoTWAS performance using GTEx models as

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

evaluated by the 3 criteria outlined above (Methods, Supplemental Note, Supplemental Figures S12-19, Supplemental Data 3-4). Overall, we observed an increase in performance of isoTWAS multivariate modeling of both isoforms and genes with increasing number of isoforms per gene, although there was less conclusive of a pattern with increasing dominant isoform fraction⁵² (Supplemental Figures S12-13, Supplemental Note, Methods). We also noticed trends in the performance gain using isoTWAS multivariate modeling with respect to both isoform and gene expression prediction across gene length, SNP density at the gene locus, and sample size (Supplemental Figures S14-16, Supplemental Note). Finally, as the proportion of non-zero effect SNPs in the isoTWAS model that are shared across isoforms increased (Supplemental Note), we found an increasing trend in the gain in prediction of gene expression using isoTWAS compared to TWAS models (Supplemental Figure S17), reflecting a similar observation from simulation. Interestingly, as this proportion increased, we found an increase in the gain in prediction of isoform expression, reinforcing the utility of multivariate modelling in marginal prediction of isoform expression. Lastly, we investigated how the robustness of isoform abundance estimation from short-read RNA-seq impacted performance gains of isoTWAS, compared with TWAS. Isoform abundance was initially quantified from probabilistic point estimates using Salmon, guided by Gencode annotations. We then assessed the performance of isoTWAS across loci binned by quantification variance measured across 50 inferential replicates from Salmon³². In general, we found that for isoform-level prediction, multivariate modeling in isoTWAS substantially outperformed univariate approaches as quantification variance increased. However, comparing isoTWAS isoform-centric and TWAS gene-centric models, there were no discernable trends in prediction of gene expression as the mean count and/or quantification variance of genes increased (Supplemental Figure S18-19, Supplemental Note). Finally, we evaluated the impact of reference transcriptome annotation fidelity by generating a synthetic dataset quantified using a reference annotation masking the dominant isoforms for a set of genes. As expected, performance of both isoTWAS and TWAS models declined when isoforms failed to be detected in expression quantification (Supplemental Note, Supplemental Figure S20).

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

Simulations support improved power and calibrated null across genetic architectures We next introduced GWAS data for complex traits into our simulation framework to benchmark the false positive rate (FPR) and power of isoTWAS (Methods). First, we found that the FPR is controlled at 0.05 for isoform-level mapping using ACAT, consistent with gene-level mapping using TWAS (Supplemental Figure S21, Supplemental Data 4). For a simulated trait, we modeled causal effect architectures for a genomic locus with 2-10 isoforms under three main scenarios (Methods; Figure 4, Supplemental Figure **S22**); (1) where the true trait effect is from only total gene expression. (2) where there is only one isoform with a non-zero effect on the trait, called the "effect isoform"; and (3) where 2 isoforms are effect isoforms, with varying magnitudes and directions of association. This first scenario showed clear increases in power for TWAS over isoTWAS, but this advantage declined as the causal proportion of isoQTLs increased and as the proportion of shared isoQTLs increased (Figure 4a, Supplemental Data 5). For scenarios (2) and (3), as effects on the trait varied across isoforms of the same gene (Figure 4b-c, Supplemental Data 6-7), we observed large increases in power for isoTWAS over TWAS. Here, across most scenarios and causal effect architectures, isoTWAS demonstrated improved power compared with gene-level TWAS, particularly when only one isoform of a gene carried a trait effect or when two effect isoforms of the same gene had different directions of effects. However, when the effect sizes of two effect isoforms of the same gene converged, TWAS and isoTWAS demonstrated similar power to detect a gene-trait association (Figure 4c). Finally, we assessed the performance of probabilistic fine-mapping in identifying the true effect isoform in our simulation framework of genes with 5 or 10 isoforms (Methods, Supplemental Figure S23, Supplemental Data 9). In general, the sensitivity of 90% credible sets (proportion of credible sets that contained the true effect isoform) was under-calibrated, likely due to difficulties in fine-mapping when QTL horizontal pleiotropy is extremely high⁵³. We found that the sensitivity of 90% credible sets decreased and the mean set size increased with increasing proportion of shared isoQTLs. Our simulation results suggest that varied isoQTL architectures and isoform-trait effects for isoforms of the same gene are key features that influence power gains in isoform-centric modeling.

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

isoTWAS increases discovery of trait associations across 15 neuropsychiatric disorders To explore our central hypothesis that isoform-centric multivariate predictive modeling will improve discovery for complex trait mapping, particularly for brain relevant traits, we next sought to apply and directly compare isoTWAS and TWAS results across 15 neuropsychiatric disorders and traits. To maximize discovery, we trained both isoTWAS and TWAS models using a greatly expanded adult brain functional genomics reference panel (N = 2,115), comprised of frontal cortex samples from PsychENCODE and AMP-AD Consortia^{27,54}, as well as using a developmental⁵⁵ pre-frontal cortex (N = 205) dataset (Methods; Figure 5). In the adult cortex, we trained models for 15,127 genes using isoTWAS passing the CV R² > 0.01 cutoff, compared with 14,283 genes using gene-level TWAS. In the developing cortex, despite a smaller sample size, isoTWAS models were successfully trained for 16,504 genes, compared with 10,535 genes using TWAS (Methods; Supplemental Table S1). We next applied these models to perform trait associations using summary statistics from 15 neuropsychiatric and brain-related GWAS⁵⁶⁻⁷⁰ (Methods, Figure 5a, Supplemental Figure S24), using the conservative stepwise hypothesis testing procedure (Figure 1a; FDR-adjusted P < 0.05 and withinlocus permutation Pacat\< 0.05). We detected far more trait-associated genes with isoTWAS compared with TWAS, across adult (2,595 vs 1,589 genes) and developmental (4,062 vs 890 genes) reference panels, respectively (Supplemental Figure S25, Supplemental Data 10-13). In total across both reference panels and all 15 traits, isoTWAS detected 3,436 unique gene and 5,377 unique isoform-trait associations (Supplemental Figure S26). In addition, of the 1,335 genes with multiple isoform-trait associations, 661 gene exhibited distinct isoform-level associations in different directions. We next sought to compare the performance of isoTWAS/TWAS in prioritizing candidate mechanisms within independent, high-confidence GWAS-significant loci⁷³. Across a combined 1,149 GWAS loci, isoTWAS identified significant associations within 323, compared with 201 detected by TWAS, a ~60% increase in discovery (Figure 5b; Methods, Supplemental Table S4). For example, of the 287 GWAS loci identified for SCZ⁷⁴, isoTWAS prioritized genes within 70 and 86 unique loci across adult and developmental reference panels, respectively, compared with 56 and 29 loci for TWAS (Figure 5b).

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

Further, across the 15 traits, 96% of gene-level TWAS associations (193/201) were concordantly identified by isoTWAS. Likewise, the standardized effect sizes for significant gene- and isoform-level associations were highly correlated (r = 0.84, $P < 2.2 \times 10^{-16}$; **Figure 5c**). Finally, to explore whether these isoTWAS-specific associations were capturing true disease signal, we compared the rate at which each method prioritized constrained genes (probability of loss-of-function intolerance, pLI ≥ 0.9; Supplemental Tables S5-S8), which are known to be substantially enriched for disease associations⁷⁵. Across adult and developmental panels for 15 traits, respectively, isoTWAS prioritized 724 and 385 constrained genes compared with 106 and 200 with TWAS, a significant increase (adult: P=0.048, developmental: P = 1.23 x 10⁻⁵, Fisher's Exact test). Altogether, these results emphasize that isoTWAS not only recovers the vast majority of TWAS associations but also greatly increases discovery of candidate GWAS mechanisms, particularly for genes intolerant to protein-truncating variation⁷⁶. In our evaluation of methods in real data, we sought to compare discovery using isoTWAS to discovery using local splicing-event based trait mapping. Briefly, for the developmental brain dataset, we first calculated intron usage using Leafcutter⁷⁷ and transformed these usage percentages to M-values⁷⁸. Then, for all introns mapped to a given gene, we used all SNPs within 1 Mb of a splicing-event to predict its usage and mapped trait associations for these splicing events using isoTWAS's multivariate framework (Methods). Overall, when aggregated to the gene-level, across 15 traits, we found that isoTWAS prioritized features at ~40% more independent GWAS loci (167 loci) than splicing-event based trait mapping (119 loci), with 108 loci (90.7%) jointly identified (Figure 5f), using the same developmental brain reference panel. Taken together, isoTWAS's specific focus on modeling isoforms of a gene provided considerable gains over considering only total gene expression or intron usage in identifying trait associations for genes and their transcript-isoforms. To investigate whether this increase in trait mapping discovery reflected true biological signal, rather than test statistic inflation due to the increased number of tests (~4-fold increase in number of tests), we next compared the null distributions across methods for results across the 15 traits (Supplemental Figure **S27).** As the genomic inflation factor is not a reliable measure in TWAS settings⁷⁹, we estimated inflation

in gene-level test statistics using an empirical Bayes approach (**Methods**). Collapsing across all 15 traits, there were no significant differences between TWAS and isoTWAS in the 95% credible intervals for test statistic inflation (**Figure 5d**). Using a heuristic to estimate increases in effective sample size (**Methods**), we observed an approximate increase in effective sample size of 10-20% when using isoTWAS compared to TWAS (**Figure 5e, Supplemental Table S9**). These analyses indicate that isoTWAS discovery is both well-calibrated to the null and facilitates increased discovery in real data compared to gene-level TWAS.

We also empirically compared probabilistic fine-mapping⁵⁵ of results from isoTWAS and gene-level TWAS (**Methods**). Here, we conducted fine-mapping on significant trait-associated genes/isoforms (adjusted P < 0.05 and permutation P < 0.05) and are within 1 Mb of one another; we term a locus with overlapping genes/isoforms a risk region. Overall, the mean number of genes in a risk region using TWAS was 3.15 compared to 3.90 using isoTWAS (**Supplemental Figure 28a**); the mean number of genes in a 90% credible set using TWAS was 1.33 compared to 1.25 using isoTWAS (**Supplemental Figure 28a**). On average, there were 1.54 isoforms per gene in a risk region and 1.27 isoforms per gene in a 90% credible set (**Supplemental Figure 28b**). Isoform-centric modeling presents unique challenges for fine-mapping due to potentially high levels of horizontal pleiotropy, and remains an important and open question for the field. Nevertheless, isoTWAS identified a relatively comparable number of genes in risk regions compared with TWAS, and the combination of conservative two-step trait mapping, permutation testing, and probabilistic fine-mapping were critical for maintaining a narrow credible set size.

isoTWAS identifies biologically-meaningful trait associations undetectable by TWAS

Overall, isoTWAS prioritized dozens of novel candidate risk genes and mechanisms in the developing and adult brain for 15 neuropsychiatric traits. These isoTWAS-prioritized genes were enriched for multiple relevant pathways consistent with the biology of the underlying trait, including cell proliferation pathways for brain volume, calcium channel activity for schizophrenia and neuroticism, and proteasome regulation in Alzheimer's Disease, among others (**Supplemental Figure S29**). We highlight below several examples of novel trait associations in which isoTWAS prioritized a highly constrained gene within a

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

GWAS locus (Supplemental Table S5-8). For example, we identified an association for SCZ with developmental expression of ENST00000519133, an isoform of SNAP91 (adjusted $P = 6.06 \times 10^{-7}$ in isoTWAS, pLI = 0.99, chromosomal location of 6q14.2), with a GWAS-significant variant rs217291 within the gene body. SNAP91 has been predicted to affect clathrin and phosphatidylinositol biding activity and synaptic vesicle recycling and has previously shown to impact synaptic development⁸⁰. In addition, we found that imputed developmental cortex expression of ENST00000476671, an isoform of KMT2E, was associated with CDG risk (adjusted $P = 7.63 \times 10^{-3}$, pLI = 1, chromosomal location of 7q22.3); the GWAS SNP rs2385537, associated in a meta-analysis of ADHD, ASD, BP, and SCZ⁸¹, is within the gene body. KMT2E regulates post-translational histone methylation of histone 3 on lysine 4A, and KMT2E heterozygous variants are associated with risk of neurodevelopmental disorders⁸². Imputed adult brain expression of ENST00000492146 (adjusted P = 1.14×10^{-6} , pLI = 0.94, chromosomal location of 3p21.1), an isoform of SFMBT1, showed a strong association with SCZ risk and contains a GWAS SNP within the gene body (rs2071044). In a recent gene-based analysis of GWAS data for SCZ and BD, decreased expression of SFMBT1 was associated with increased risk of both disorders⁸³, consistent with the effects for the isoform we identify in this isoTWAS analysis. Lastly, our analysis implicated ENST00000537270, an isoform of KMT5A (pLI = 0.99, found in 12q24.31), in an association with SCZ risk. KMT5A, a H4K20 methyltransferase, has been previously implicated in GWAS for SCZ but cis-eQTLs of the gene have not be colocalized with the GWAS signal previously^{74,84,85}. As evidenced by our simulation analyses, a main advantage of isoTWAS over TWAS is the identification of trait associations for isoforms of genes, where the gene itself is not associated with the trait. We illustrate several examples of isoforms prioritized by isoTWAS, all in adult cortex, for genes with limited or distinct expression QTLs (Figure 6, Supplemental Figure S30, Supplemental Data 14). First, we detected a strong SCZ association with ENST00000492957, an isoform of AKT3 (pLI = 1) at 1q43-q44. which encodes a serine/threonine-protein kinase that regulated many processes like metabolism and cell growth, proliferation, and survival. AKT3 has shown effects on anxiety, spatial and contextual memory, and fear extinction in mice, such that loss-of-function of AKT3 causes learning and memory deficits^{86,87}. Within the GWAS locus, there was a strong overlapping isoQTL signal (P < 10⁻⁵⁰); however, the eQTL

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

signal includes only a single SNP that reaches P < 10⁻⁶, which is in low LD with the GWAS-significant SNPs in the locus (Figure 6a). The lead isoQTL (rs4430311) showed a significant, negative association with ENST00000492957, but not AKT3 expression, with increasing SCZ risk alleles. However, this SNP has only a nominally significant positive association with AKT3, as the number of alternative alleles at the SNP increased. Interestingly, a different isoform of AKT3 (ENST00000681794) was prioritized in an association with BV, which also has a GWAS hit at this locus (Supplemental Figure S30). The two distinct isoforms of AKT3 have distinct 3' transcript structures, particularly close to the lead isoQTL of ENST00000681794. These results suggest a complex role of AKT3 isoforms with brain-related traits to be explored further computationally and experimentally. Similarly, we found a strong isoQTL signal for ENST00000409096 but a weak eQTL signal of CUL3 in the 2q36.2 locus (pLI = 0.99), in another association with SCZ (Figure 6b). CUL3 is a component of Cullin-RING E3 ubiquitin ligase complexes, involved in protein ubiquitylation, cell cycle regulation, protein trafficking, signal transduction, and transcription. Previous work has implicated CUL3 dysregulation as a pathological mechanism for both SCZ and ASD risk⁸⁸. Next, an isoform ENST00000678969 of HSPD1, encoding a mitochondrial heat shock protein, was associated with SCZ risk (adjusted $P = 8.79 \times 10^{-12}$, pLI = 0.99, 2q33.1) and showed a similar pattern across GWAS, eQTL, and isoQTL signals (Figure 6c). HSPD1 was identified in 3 independent secondary analyses of SCZ GWAS data, is among multiple non-MHC immune genes implicated in SCZ, and has roles in brain hypomyelination⁸⁹. Our work adds to these previous studies by implicating a specific isoform of HSPD1 at the locus. Lastly, ENST00000423517, an isoform of PCLO, was associated with multiple traits in the CDG analysis (meta-analysis of ADHD, BP, MDD, and SCZ; adjusted P = 1.83 x 10⁻⁴, pLI = 1). Again, we found a strong isoQTL but not eQTL signal, with the CDG risk allele negatively associated with isoform expression. PCLO is involved in the presynaptic cytoskeletal matrix, establishing active synaptic zones, and synaptic vesicle trafficking; rare variants of PCLO in diverse populations have been recently implicated in risk of SCZ and ASD^{90,91}. Altogether, these results highlight the importance of incorporating isoform-level regulation for prioritizing novel candidate GWAS risk mechanisms, as implemented in our isoTWAS framework.

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

DISCUSSION In this work, we introduce isoTWAS, a scalable framework that integrates genetic and isoform-level transcriptomic variation with GWAS to not only identify genes whose expression are associated with a trait but also prioritize a set of isoforms of the gene that best explains the association. We provide an extensive set of isoform-level predictive models (https://zenodo.org/record/679594792) and software to conduct isoform-level trait mapping with GWAS summary statistics (https://github.com/bhattacharya-abt/isoTWAS). As demonstrated above, isoTWAS presents several advantages over traditional gene-level TWAS or simple univariate modeling of isoform expression. First, modeling expression at the isoform-level can detect isoQTL architectures that vary across isoforms and thus may not be captured by eQTLs of a gene. Second, joint multivariate isoform-level modeling improved predictive accuracy of isoform and total gene expression, both in simulated and real data with independent replication. Third, aggregating isoform-level associations to the gene-level through ACAT substantially increased power to detect trait associations over traditional TWAS. We attribute this increase in power to several key features: first, isoform-level modeling in isoTWAS increases the number of imputable genes by >2-fold; second, isoTWAS models improve accuracy of gene-level prediction by as much as 35%; third, isoTWAS jointly models both expression and splicing regulation, thereby capturing multiple potential underlying complex trait mechanisms. Finally, as genetic control of isoform expression and usage are often much more tissueand cell-type-specific than eQTLs^{26,37}, we hypothesize that isoTWAS is more capable of uncovering such context-specific trait associations. Recent work has highlighted the promise of alternative splicing as a biological mechanism underlying complex traits not fully captured through eQTLs^{24,26,27,93}. Splicing-QTL integration is a promising vehicle to prioritize alternative exons or splice sites that may explain the genetic association with a trait, but a single exon or splice site can correspond to multiple isoforms of the same gene. Mapping genetic regulation at the exon- rather than gene-level often leads to more detected signal⁹⁴. However, most of

these analyses have focused on local splicing events or exon-level inclusion, rather than the combined

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

consequences of these events - namely, different isoforms of the same gene. Local splicing events can be computationally intensive to measure and are difficult to systematically integrate across multiple distinct large-scale datasets, which is necessary for achieving sample sizes sufficient for interrogation of population-level allelic effects^{27,28}. Furthermore, multiple splicing changes are often coordinated across a gene, yielding many non-independent features that increase multiple testing burden. Our results demonstrate that isoform-centric trait mapping with isoTWAS increases discovery by ~40% compared with a matched local splicing event-based analysis, although these methods may recover some independent signal. Future work should consider integrating both reference-guided and annotation-free approaches for quantification and detection of isoform and splicing patterns to develop more nuanced mechanistic hypotheses for GWAS loci. We conclude with some limitations of and future considerations for isoTWAS. First, we note that isoformlevel expression quantifications are maximum-likelihood estimates, due to the inherent limitations of short-read RNA-seq. These estimates are generally guided by existing transcriptome annotations (e.g., GENCODE) and thus are dependent on the completeness and accuracy of these genomic annotations. Further, many dataset-specific sequencing factors may will affect the accuracy of these estimates, especially sequencing depth, read length and library preparation (mRNA vs total RNA sequencing). The continued emergence of long-read sequencing platforms, including PacBio IsoSeq and Oxford Nanopore Technologies, will be instrumental for improving reference transcriptome annotations, particularly with tissue specificity, which will in turn improve isoTWAS. Further, as these methods continue to gain scalability and cost effectiveness, they will ultimately replace short-read sequencing (and isoform estimation) for population-scale datasets. As isoTWAS is agnostic to the method of isoform expression quantification, this framework will continue to be applicable as we approach this long read sequencing era. Recent analyses have shown that larger sample sizes may outweigh sequencing coverage for eQTL mapping, but this relationship has not been investigated for isoform-level expression⁹⁵. Thus, for optimal discovery with isoTWAS, the appropriate balance between sample size and reference panel sequencing depth remains to be determined.

Second, while inferential replicates from RNA-seq quantification can provide measures of technical variation, they are not incorporated into the predictive models. Our analyses of prediction across inferential replicates suggest a methodological opportunity: leveraging these inferential replicates as a measure of quantification error may help in estimating the robustness of isoform prediction and, potentially, of the precision of these SNP effects. A more flexible predictive model that estimates standard errors for SNP effects by model-averaging across the replicate datasets may help with trait mapping by providing a prediction interval for both isoform- and gene-level imputed expression. Third, just as TWAS can be cast as a differential gene expression analysis conducted with imputed expression, isoform-level trait mapping is akin to differential transcript expression analysis. An analogous goal of isoTWAS can be to detect trait associations with genetically-regulated transcript usage. However, it is unclear if the compositional nature of transcript usage data needs to accounted for at the prediction step or the trait mapping steps⁹⁶. Lastly, as we show, this framework can suffer from reduced power, inflated false positives, and reduced sensitivity in fine-mapping in the presence of SNP horizontal pleiotropy, where the genetic variants in the isoform expression model affect the trait, independent of isoform expression, or when multiple SNPs affect expression of isoforms^{97,98}. For pathways that are not observed or accounted for in the reference expression panel and GWAS, accounting for horizontal pleiotropy may improve trait mapping. We motivate further methodological extensions of probabilistic fine-mapping to reconcile pleiotropy for SNPs shared across models for multiple isoforms at the same genetic locus, as summarystatistic based methods that control for horizontal pleiotropy are not yet effective 99.

In sum, isoTWAS provides a novel framework to scalably interrogate the transcriptomic mechanisms underlying genetic associations with complex traits and generate biologically-meaningful and testable hypotheses about disease risk mechanisms. Based on our results, we emphasize a shift in focus from quantifications of the transcriptome on the gene-level to the transcript-isoform level to maximize discovery of transcriptome-centric genetic associations with complex traits.

METHODS

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

isoTWAS consists of three steps: (1) training predictive models of isoform expression, (2) imputing isoform-specific expression into a separate GWAS panel, and (3) association testing between imputed expression and a phenotype (**Figure 1b**). isoTWAS contrasts with TWAS as it models correlations between the expression of isoforms of the same gene. We outline each step below, with further mathematical details in **Supplemental Methods**.

Training predictive models of isoform expression

Model and assumptions

Assume a given gene G has M isoforms with expression levels across N samples, with each sample having R inferential replicates. Let Y_G^* be the $N \times M$ matrix of mean isoform expression (log-scale TPM) for the N samples and M isoforms, using the point estimates from the Expectation-Maximization algorithm of a pseudo-mapping quantification algorithm, like Salmon or kallisto^{32,33}. We can jointly model isoform expression with a system of $N \times M \times R$ equations. For sample $n \in \{1, ..., N\}$, isoform $m \in \{1, ..., M\}$ of gene G, and replicate $r \in \{1, ..., R\}$, we have:

$$y_{nmr} = x_n \beta_m + \epsilon_{nmr} \quad (1),$$

where y_{nmr} is the expression of isoform m for the rth inferential replicate of sample n, x_n is the P-vector (vector of length P) of cis-genotypes in a 1 Mb window around gene G, β_m is the P-vector of genetic effects of the P genotypes on isoform expression, and ϵ_{nmr} is normally distributed random noise with mean 0 and variance σ_{nmr}^2 . We standardize both the genotypes and the isoform expression to mean 0 and variance 1. As the SNP vector x_n does not differ across inferential replicates, we impose the following assumptions on the variance-covariance matrix of $\epsilon = \left(\epsilon_{1,1,1}, \epsilon_{1,1,2}, \ldots, \epsilon_{nmr}\right)^T$, the vector of random errors: we assume that ϵ_{nmr} are independent and identically distributed across samples $n \in \{1, \ldots, N\}$ and identically distributed across replicates $r \in \{1, \ldots, R\}$. Accordingly, the point estimates of the SNP effects on isoform expression are not influenced by differences in expression across replications. Therefore, in matrix form, we consider the following predictive model:

$$Y_G^* = X_G B_G + E_G (2)$$

Here, X_G is the $N \times P$ matrix of genotype dosages, B_G is the $P \times M$ matrix of SNP effects on isoform expression and E_G is a matrix of random errors, such that $vec(E_G) \sim N_{NM}(0, \Sigma = \Omega^{-1} \otimes I_N)$. Σ represents

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

the variance-covariance matrix in the errors (with precision matrix $\Omega = \Sigma^{-1}$), following the aforementioned independence assumptions. Estimating SNP effects on isoform expression We apply 5 different methods to estimate \hat{B}_G , the matrix of SNP effects on isoform expression. The first four are multivariate methods that model the isoforms jointly; the last method models each isoform separately using univariate methods. The goal of this SNP effect estimation is marginal prediction, i.e., leveraging the correlation between isoforms to improve prediction of each isoform separately. The \hat{B}_G matrix that gives the largest adjusted R2 in 5-fold cross-validation across the 5 methods is selected as the final model to predict isoform expression for a given gene. In settings where we are interested in predicting gene-level expression from these predicted isoforms, isoTWAS trains an elastic net penalized linear regression that predicts gene-level expression from genetically-predicted isoform-level expression; this model training is conducted across the same 5 folds to prevent data leakage¹⁰⁰. We provide an overview of the methods, with mathematical details in Supplemental Methods: 1. Multivariate elastic net (MVEnet) regression: This is an extension of elastic net, where the response is a matrix of correlated responses⁴³. Here, the absolute penalty is imposed on each single coefficient by a group-lasso penalty on each vector of SNP effects across isoforms (rows of B_G); accordingly, a SNP can only have a non-zero effect on an isoform if it has a non-zero effect on all isoforms. 2. Multivariate LASSO Regression with covariance estimation (MRCE): We adapt Rothman et al's proposed procedure to simultaneously and iteratively estimate both \hat{B}_G , the SNP effects matrix, and $\hat{\Omega}$, the precision matrix⁴⁴. This procedure accounts for the correlation between isoforms but does not impose the group-lasso penalty as in MVEnet. As such, a single SNP need not have a non-zero effect on all isoforms. 3. Multivariate elastic net with stacked generalization (joinet): We use Rauschenberger and Glaab's joinet method that uses a two-step prediction⁴⁵. In the first step, the design matrix of SNPs is used to generate a cross-validated prediction of each isoform. In the second step, the matrix of predicted isoform expression is used to predict each isoform.

- 4. Sparse partial least squares (SPLS): This is an implementation of partial least squares with a sparsity penalty, that attempts to find an optimal latent decomposition for the linear relationship between the matrix of isoform expression and the design matrix of SNPs. We use the Chun and Keles's implementation from the spls R package⁴⁶.
- 5. *Univariate FUSION*: the simplest implemented method is the univariate predictive modelling used in FUSION². We disregard the correlation structure between isoforms and train a univariate elastic net⁴³, estimation of the best linear unbiased predictor (BLUP) in a linear mixed model¹⁰¹, and SuSiE⁴⁷ predictive model for each isoform separately. The model with the largest adjusted R² out of these three models is outputted. This approach serves as a baseline measurement for prediction of each isoform independently.

Trait association and step-wise hypothesis testing

We note that the tests of association in isoTWAS are similar to tests in differential transcript expression analyses, as TWAS tests of association are analogous to tests in differential gene expression analyses. isoTWAS and TWAS are distinct, as these methods consider imputed isoform and gene expression, respectively, as predicted by the trained expression models. If individual-level genotypes are available in the external GWAS panel, isoform expression can be directly imputed by multiplying the SNP weights from the predictive model with the genotype dosages in the GWAS panel. If only summary statistics are available, we adopt the weighted burden test from Gusev et al with an ancestry-matched linkage disequilibrium panel^{4,98}. Compared to TWAS, a main distinction for isoTWAS association testing is the increased number of tests (approximately 4-fold the number of isoforms than genes)²¹ and the potential correlation in test statistics for isoforms of the same gene.

Accordingly, we perform a two-step hypothesis testing framework (**Supplemental Figure S2**)¹⁰². In the first step, for every isoform with a trained model, we generate a TWAS test statistic using either linear regression for GWAS with individual-level genotypes or the weighted burden test for GWAS with only summary statistics⁴. Given the t test statistics $T_1, ..., T_t$ for a single gene, we used an omnibus test to aggregate the t test statistics into a single P-value for a gene. We benchmark different omnibus tests in

simulations, but the default omnibus test in isoTWAS is aggregated Cauchy association test (ACAT)⁴⁹. We control for false discovery across all genes via the Benjamini-Hochberg procedure, but the Bonferroni procedure can also be applied for more conservative false discovery control. In the second step, for isoforms for genes with an adjusted omnibus P < 0.05, we employ Shaffer's modified sequentially rejective Bonferroni (MSRB) procedure to control the within-gene family-wide error rate. At the end of these two steps, we identify a set of genes and their isoforms that are associated with the trait.

Control for false positives within GWAS loci

In TWAS and related methods, association statistics have been shown to be well calibrated under the null of no GWAS association. However, within loci harboring significant GWAS signal, false positive associations can result when eQTLs and GWAS coincide within overlapping LD blocks. To address this, we have adopted two conservative approaches to control for type 1 error within GWAS loci, namely (1) permutation testing and (2) probabilistic fine mapping. The permutation testing approach, adopted from Gusev et al⁴, is a highly conservative test of the signal added by the SNP-transcript effects from the predictive models, conditional on the GWAS architecture of the locus. Briefly, we shuffle the SNP-transcript effects in the predictive models 10,000 times and generate a null distribution for the TWAS test statistic for each isoform. We then use this null distribution to generate a permutation-based P-value for the original test statistic for each isoform. Additionally, we aggregate these null distributions using an omnibus test and compare the omnibus P-value to this distribution to generate permutation P-value for each gene. Finally, we can employ isoform-level probabilistic fine-mapping using methods from FOCUS⁵⁵ to generate credible set of isoforms that explain the trait association at a locus. We only run isoform-level fine-mapping for significantly-associated isoforms in overlapping 1 Megabase windows.

Simulation framework

We adopt techniques from Mancuso et al's $twas_sim$ protocol¹⁰³ to simulate multivariate isoform expression based on randomly simulated genotypes and environmental random noise. First, for n samples, we generate a matrix of genotype dosages for the SNPs within 1 Megabase of 22 different

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

genes (1 per chromosome) using an LD reference panel of European subjects from 1000 Genomes Project⁵¹. Next, we generate a matrix of SNP-isoform effects across different causal SNP proportions p_c , numbers of isoforms t, and p_s proportion of the SNP-isoform effects being shared across isoforms of the same gene. We then add two matrices of random noise U and ϵ . The first matrix U noise represents non cisgenetic effects on isoforms that are correlated between samples and isoforms; we control the proportion of variance explained in isoform expression attributed to U using a parameter σ_h . The second matrix ϵ is a matrix of random noise that is independent for each isoform, such that $\epsilon_i \sim N(0, \sigma_e^2 I)$ where $\sigma_e^2 = 1$ $\sigma_h - h_q^2$. We generate 10,000 simulations for each configuration of the simulation parameters, varying $n \in$ $\{200, 500\}, p_c \in \{0.001, 0.01, 0.05\}, h_q^2 \in \{0.05, 0.10, 0.25\}, p_s \in \{0, 0.5, 1\}, \text{ and } \sigma_h \in \{0.1, 0.25\}.$ Full mathematical details are provided in Supplemental Methods and summarized in Figure 2. We also generate traits under three distinct scenarios, with a continuous trait with heritability $h_t^2 \in$ {0.01,0.05,0.10} and a GWAS sample size of 50,000 (**Supplemental Methods**): 1. Only gene-level expression has a non-zero effect on trait. Here, we sum the isoform expression to generate a simulated gene expression. We randomly simulate the effect size and scale the error to ensure trait heritability. 2. Only 1 isoform has a non-zero effect on the trait. Here, we generate a multivariate isoform expression matrix with 2 isoforms and scale the total gene expression value such that one isoform (called the effect isoform) makes up $p_a \in \{0.10, 0.30, 0.50, 0.70, 0.90\}$ proportion of total gene expression. We then generate effect size for one of the isoforms and scale the error to ensure trait heritability. 3. Two isoforms with different effects on traits. Here, we generate a multivariate isoform expression matrix with 2 isoforms that make up equal portions of the total gene expression. We then generate an effect size of α for one isoform and $p_e\alpha$ for the other isoform, such that $p_e \in \{-1, -0.5, -0.2, 0.2, 0.5, 1\}$. We then scale the error to ensure trait heritability.

Lastly, to estimate the approximate false positive rate (FPR), we followed the same simulation framework to generate eQTL data and GWAS data. In the GWAS data, however, we set the effect of gene- and isoform-level imputed expression to 0 to generate a simulated trait under the null, where the gene and isoforms are not associated with the trait. We then estimate the FPR by calculating the proportion of gene-trait associations at P < 0.05 under this null across 20 sets of 1,000 simulated GWAS panels. We also assess isoform-level fine-mapping using FOCUS in a scenario with a gene with 5 or 10 isoforms and a single effect isoform. We compute the sensitivity of 90% credible sets of isoforms (proportion of credible sets that contain the effect isoform) and the number of isoforms in the 90% credible set.

GTEx processing and model training

We quantified GTEx v8³⁷ RNA-Seq samples for 48 tissues using Salmon v1.5.2³² in mapping-based mode. We first built a Salmon index for a decoy-aware transcriptome consisting of GENCODE v38 transcript sequences and the full GRCh38 reference genome as decoy sequences²¹. Salmon was then run on FASTQ files with mapping validation and corrections for sequencing and GC bias. We computed 50 inferential bootstraps for isoform expression using Salmon's Expectation-Maximization algorithm. We then imported Salmon isoform-level quantifications and aggregated to the gene-level using tximeta⁴¹. Using edgeR, gene and isoform-level quantifications underwent TMM-normalization, followed by transformation into a log-space using the variance-stabilizing transformation using DESeq2^{104,105}. We then residualized isoform-level and gene-level expression (as log-transformed CPM) by all tissue-specific covariates (clinical, demographic, genotype PCs, and expression PEER factors) used in the original QTL analyses in GTEx. We calculated the quantification variance across inferential replicates using the computeInfRV() function from the fishpond package¹⁰⁶. We computed the isoform fraction using the isoformTolsoformFraction() function from the IsoformSwitchAnalyzeR package⁵⁴.

SNP genotype calls were derived from Whole Genome Sequencing data for samples from individuals of European ancestry, filtering out SNPs with minor allele frequency (MAF) less than 5% or that deviated from Hardy-Weinberg equilibrium at $P < 10^{-5}$. We further filtered out SNPs with MAF less than 1% frequency among the European ancestry samples in 1000 Genomes Project⁵¹.

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

Details of the model training pipeline for GTEx are similar to those summarized in Supplemental Figure **\$10.** Gene-level univariate models were trained using elastic net regression⁴³, best linear unbiased predictor (BLUP) in a linear mixed model⁴⁸, and SuSiE⁴⁷, using all SNPs within 1 Mb of the gene body^{4,43,47,101}. For each gene, the best performing model was chosen based on McNemar's adjusted 5fold cross-validation (CV) R². We selected only genes with CV R² ≥ 0.01. We applied multivariate modeling outlined in isoTWAS to train isoform-level predictive models, selecting only those isoform models with CV $R^2 \ge 0.01$ (Supplemental Figure S2). All isoTWAS models generated are publicly available (see Data Availability). Developmental brain reference panel processing and model training We quantified developmental frontal cortex²⁴ (N = 205) RNA-Seg samples using Salmon v1.8.0³² in mapping-based mode. We used the same indexed transcriptome as in the GTEx analysis and ran Salmon with mapping validation and corrections for sequencing and GC bias. We computed 50 inferential bootstraps for isoform expression using Salmon's Expectation-Maximization algorithm. We then imported Salmon isoform-level quantifications and aggregated to the gene-level using tximeta⁴¹. Using edgeR, gene and isoform-level quantifications underwent TMM-normalization, followed by transformation into a log-space using the variance-stabilizing transformation using DESeg2^{104,105}. We then residualized isoform-level and gene-level expression (as log-transformed CPM) by covariates (age, sex, 10 genotype PCs, 90 and 70 hidden covariates with prior, respectively). Typed SNPs with non-zero alternative alleles, MAF > 1%, genotyping rate > 95%, HWE P < 10^{-6} were first imputed to TOPMed Freeze 5 using minimac4 and eagle v2.4^{107,108}. We then retained biallelic SNPs with imputation accuracy R² > 0.8, with rsIDs. Finally, we filtered out SNPs with MAF < 0.05 or that deviated from Hardy-Weinberg equilibrium at $P < 10^{-6}$. Adult brain reference panel processing and model training Matched genotype and RNAseg data from adult brain cortex tissue from n = 2,365 individuals were compiled and processed from the PsychENCODE Consortium²² and the Accelerating Medicines

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

Partnership Program for Alzheimer's Disease (AMP-AD)⁵⁶, consisting of the individual studies BipSeg, BrainGVEX, CommonMind Consortium (CMC), CommonMind Consortium's National Institute of Mental Health Human Brain Collection Core (CMC HBCC), Lieber Institute for Brain Development-szControl (LIBD_szControl), UCLA-ASD, Religious Orders Study and the Memory and Aging Project (ROSMAP), Mount Sinai Brain Bank (MSBB) and MayoRNAseq. Typed genotypes were lifted over to the GRCh38 build using CrossMap v.0.6.3¹⁰⁹ and then filtered to remove variants where the reference allele matched any of the alternate alleles. Genotype data from whole genome sequencing (BrainGVEX, UCLA-ASD, ROSMAP, MSBB, and MayoRNAseg) was further filtered to variants present on the Infinium Omni5-4 v1.2 array in order to satisfy the imputation server's maximum limit of 20,000 typed variants per 20Mb. All genotype data was further processed with PLINK v1.90b6.21 110 , removing variants with HWE P < 10^{-6} , MAF< 0.01 or missingness rate > 0.05, and removing samples with missingness rate > 0.1 across typed variants or missingness rate > 0.5 on any individual chromosome. Genotype data was prepared for imputation using the McCarthy Group's HRC-1000G-check-bim-v4.3.0 tool against freeze 8 of the Trans-Omics for Precision Medicine (TOPMed) reference panel¹¹¹. The tool removes A/T and G/C SNPs with MAF > 0.4, variants with alleles that differ from the reference panel, variants with an allele frequency difference > 0.2 from the reference panel and variants not in the reference panel. Additionally, the tool updates strand, position and reference/alternate allele assignment to match the reference panel. Genotypes were then passed into the TOPMed Imputation Server by individual array batch¹¹². The genotypes were phased with Eagle v2.4 and imputed with Minimac4 using the TOPMed reference panel^{107,108}. Further QC was performed on the imputed genotypes using bcftools v1.11 and PLINK. The imputed genotypes were filtered to well-imputed variants with R2 > 0.8. The arrays were merged after filtering to variants that were well-imputed in all arrays to be merged. Only arrays with at least 400,000 variants after pre-imputation QC were merged in order to prevent too many variants from dropping out. The merged genotype data was then converted to PLINK 1 binary format and further processed with PLINK, removing variants with duplicates, HWE P $< 10^{-6}$, MAF < 0.01 or missingness rate > 0.05 and

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

removing samples with missingness rate > 0.1. Samples from the same individual were identified by calculating the genetic relatedness matrix using SnpArrays.il and finding sets of samples with relatedness > 0.75. From each set of replicates, only the genotyped sample from the array with the most variants after pre-imputation QC was kept. For model training, only SNPs annotated in HapMap3 were retained 113. RNAseq paired reads from each study were sorted by name and then converted to FASTQ format using samtools v1.14¹¹⁴. The reads were then quantified using salmon v1.8.0 in mapping-based mode using a full decoy indexed from GENCODE v38 transcriptome and GRCh38 patch 13 assembly 32. Quantification was run using standard EM algorithm with library type automatically inferred and estimates adjusted for sequence-specific and fragment-level GC biases. Bootstrapped abundance estimates were calculated using 50 bootstrap samples. Isoform-level expression was summarized to the gene-level using tximeta¹¹⁵. Only isoforms with 0.1 TPM for more than 75% of samples were retained. The resulting expression was normalized using the variance-stabilizing transformation from DESeq2¹⁰⁵. Samples with WGCNA network connectivity scores of less than -3 were removed as outliers, resulting in a total of 2,115 samples¹¹⁶. Isoform- and gene-level expression was then batch-corrected using ComBat, using study site as the batch¹¹⁷. Lastly, age, sex, squared age, 10 genotype PCs, and 200 (for gene expression) and 175 (for isoform expression) hidden covariates with prior (using sequencing metrics from PicardTools to estimate the prior) were removed from the expression 118,119. The number of hidden covariates with prior (HCP) were selected by optimizing the number of nominal cis-gene-level expression QTLs and cis-isoform-level expression QTLs at Bonferroni-corrected P < 0.05, respectively, on a grid from 100 to 300 HCPs, as detected by QTLtools¹²⁰. Details of the model training pipeline are summarized are equivalent to those used to train models in GTEx data. All isoTWAS models generated are available at https://zenodo.org/record/679594792. Gene- and isoform-level trait mapping We conducted gene- and isoform-level trait mapping for 15 neuropsychiatric traits: attention-deficit hyperactivity disorder (ADHD, N_{cases} = 20,183/N_{controls} = 35,191)⁵⁹, Alzheimer's disease (ALZ,

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

90,338/1,036,225)⁶⁰, anorexia nervosa (AN, 16,992/55,525)⁷², autism spectrum disorder (ASD, 18,381/27,969)⁵⁸, bipolar disorder (BP, 41,917/371,549)⁶¹, brain volume (BV, N = 47,316)⁶², crossdisorder (CDG, 232,964/494,162)⁶³, cortical thickness (CortTH, N = 51,665)⁶⁴, intracranial volume (ICV, N = 32,438)⁶⁵, major depressive disorder (MDD, 246,363/561,190)⁶⁶, neuroticism (NTSM, N = 449,484)⁶⁷, obsessive compulsive disorder (OCD, 2,688/7,037)⁶⁸, panic and anxiety disorders (PANIC, 2,248/7,992)⁶⁹, post-traumatic stress disorder (PTSD, 32,428/174,227)⁷⁰, and schizophrenia (SCZ, 69.369/236.642)⁷¹. For gene-level trait mapping, we used the weighted burden test, followed by the permutation test, as outlined by Gusev et al⁴. For isoform-level trait mapping, we used the stage-wise testing procedure outlined in the isoTWAS method. In-sample LD from the QTL reference panels was used to calculate the standard error in the weighted burden test. For isoforms, irrespective of their corresponding genes, passing both stage-wise tests and the permutation test, we employed isoform-level probabilistic fine-mapping using FOCUS with default parameters⁵⁵. These methods are summarized in Supplemental Figure S24. We estimated the percent increase in effective sample size by employing the following heuristic. We convert gene-level association P-values into χ^2 test statistics with 1 degree-of-freedom. For $\chi^2 > 1$, we then calculate the percent increase for isoTWAS-based associations versus TWAS-based associations. As the mean of the χ^2 distribution is linearly related to power and sample size¹²¹, we can use this percent increase in test statistic as a measure of power or effective sample size. We defined independent genome-wide significant SNPs in GWAS by LD clumping with lead GWAS SNP < 5 x 10⁻⁸ with P-value used for ranking and a R² threshold of 0.2. **DATA AVAILABILITY** GTEx genetic, transcriptomic, and covariate data were obtained through dbGAP approval at accession number phs000424.v8.p2. Linkage disequilibrium reference data from the 1000 Genomes Project were obtained at this link: https://www.internationalgenome.org/data-portal/sample. GWAS summary statistics were obtained at the following links: ADHD (https://www.med.unc.edu/pgc/download-results/), ALZ (https://ctg.cncr.nl/software/summary statistics/), AN (http://www.med.unc.edu/pgc/results-and-

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

downloads), ASD (https://www.med.unc.edu/pgc/download-results/), BP (https://www.med.unc.edu/pqc/download-results/), BV (https://ctg.cncr.nl/software/summary statistics), CDG (https://www.med.unc.edu/pac/results-and-downloads), CortTH (https://enigma.ini.usc.edu/research/download-enigma-gwas-results/), ICV (https://enigma.ini.usc.edu/research/download-enigma-gwas-results/), MDD (http://dx.doi.org/10.7488/ds/2458), NTSM (https://ctg.cncr.nl/software/summary statistics/neuroticism summary statistics), OCD (https://www.med.unc.edu/pgc/download-results/), PANIC (https://www.med.unc.edu/pgc/downloadresults/), PTSD (https://www.med.unc.edu/pgc/results-and-downloads/), and SCZ (https://www.med.unc.edu/pgc/download-results/). The Developmental Brain RNA-seg and genotype dataset from Walker et al is available at dbGAP with accession number phs001900. The subset of Adult Brain RNA-seq and genotype data from the PsychENCODE Consortium is available at https://psychencode.synapse.org/DataAccess and from AMP-AD is available at https://adknowledgeportal.synapse.org/Data%20Access. GWAS summary statistics and accession numbers to genotype and RNA-seq data are provided in Supplemental Table S10. isoTWAS models for 48 tissues from GTEx are available at https://zenodo.org/record/8047940¹²², adult brain cortex from PsychENCODE and AMP-AD are available at https://zenodo.org/record/8048198123, and developmental brain cortex from Walker et al are available at https://zenodo.org/record/8048137¹²⁴. **CODE AVAILABILITY** isoTWAS is available as an R package at https://github.com/bhattacharya-a-bt/isotwas. Sample scripts for analyses are available at https://github.com/bhattacharya-a-bt/isotwas manu scripts. **REFERENCES** 1. Sullivan, P. F. et al. Psychiatric Genomics: An Update and an Agenda. The American journal of psychiatry 175, 15-15 (2018). 2. Tam, V. et al. Benefits and limitations of genome-wide association studies. Nat Rev Genet 20, 467-484 (2019).

- 810 3. Gamazon, E. R. et al. A gene-based association method for mapping traits using reference
- 811 transcriptome data. *Nature Genetics* **47**, 1091–1098 (2015).
- 4. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association studies.
- 813 Nature Genetics **48**, 245–252 (2016).
- 5. Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene expression
- variation inferred from GWAS summary statistics. *Nature Communications* **9**, 1–20 (2018).
- 816 6. Hu, Y. et al. A statistical framework for cross-tissue transcriptome-wide association analysis. Nature
- 817 *Genetics* **51**, 568–576 (2019).
- 818 7. Zhou, D. et al. A unified framework for joint-tissue transcriptome-wide association and Mendelian
- randomization analysis. *Nature Genetics* **52**, 1239–1246 (2020).
- 820 8. Barbeira, A. N. et al. Integrating predicted transcriptome from multiple tissues improves association
- 821 detection. *PLoS Genetics* **15**, e1007889 (2019).
- 9. Bhattacharya, A., Li, Y. & Love, M. I. MOSTWAS: Multi-Omic Strategies for Transcriptome-Wide
- 823 Association Studies. *PLOS Genetics* **17**, e1009398 (2021).
- 824 10. Gusev, A. et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields
- mechanistic disease insights. *Nature Genetics* **50**, 538–548 (2018).
- 826 11. Wu, L. et al. A transcriptome-wide association study of 229,000 women identifies new candidate
- susceptibility genes for breast cancer. *Nature genetics* **50**, 968–978 (2018).
- 12. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic Association
- Studies Using Summary Statistics. *PLoS Genetics* **10**, e1004383–e1004383 (2014).
- 13. Gleason, K. J., Yang, F., Pierce, B. L., He, X. & Chen, L. S. Primo: Integration of multiple GWAS and
- omics QTL summary statistics for elucidation of molecular mechanisms of trait-associated SNPs and
- detection of pleiotropy in complex traits. Genome Biology 21, 236–236 (2020).
- 14. He, X. et al. Sherlock: Detecting gene-disease associations by matching patterns of expression QTL
- and GWAS. American Journal of Human Genetics **92**, 667–680 (2013).
- 835 15. Hormozdiari, F. et al. Colocalization of GWAS and eQTL Signals Detects Target Genes. American
- 836 Journal of Human Genetics **99**, 1245–1260 (2016).

- 837 16. Umans, B. D., Battle, A. & Gilad, Y. Where Are the Disease-Associated eQTLs? Trends in Genetics
- 838 **37**, 109–124 (2021).
- 839 17. Barrera, L. O. et al. Genome-wide mapping and analysis of active promoters in mouse embryonic
- stem cells and adult organs. *Genome Res* **18**, 46–59 (2008).
- 18. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470-
- 842 476 (2008).
- 19. Melé, M. et al. The human transcriptome across tissues and individuals. Science 348, 660–665
- 844 (2015).
- 20. Merkin, J., Russell, C., Chen, P. & Burge, C. B. Evolutionary dynamics of gene and isoform
- regulation in mammalian tissues. *Science* **338**, 1593–1599 (2012).
- 21. Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic
- 848 Acids Res **47**, D766–D773 (2019).
- 849 22. Gandal, M. J. et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and
- bipolar disorder. *Science* **362**, (2018).
- 851 23. Wang, D. et al. Comprehensive functional genomic resource and integrative model for the human
- 852 brain. Science **362**, (2018).
- 853 24. RL, W. et al. Genetic Control of Expression and Splicing in Developing Human Brain Informs Disease
- 854 Mechanisms. Cell **179**, 750-771.e22 (2019).
- 855 25. Leung, S. K. et al. Full-length transcript sequencing of human and mouse cerebral cortex identifies
- widespread isoform diversity and alternative splicing. Cell Rep 37, 110022 (2021).
- 857 26. Li, Y. I. et al. RNA splicing is a primary link between genetic variation and disease. Science 352,
- 858 600–604 (2016).
- 859 27. Gandal, M. J. et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and
- 860 bipolar disorder. *Science* **362**, (2018).
- 861 28. Wang, D. et al. Comprehensive functional genomic resource and integrative model for the human
- 862 brain. *Science* **362**, (2018).
- 29. Barbeira, A. N. et al. Exploiting the GTEx resources to decipher the mechanisms at GWAS loci.
- 864 Genome Biology 2021 22:1 22, 1–24 (2021).

- 30. MM, S. & MS, S. RNA mis-splicing in disease. *Nature reviews. Genetics* 17, 19–32 (2016).
- 866 31. Akula, N. et al. Deep transcriptome sequencing of subgenual anterior cingulate cortex reveals cross-
- diagnostic and diagnosis-specific RNA expression changes in major psychiatric disorders.
- 868 Neuropsychopharmacol. **46**, 1364–1372 (2021).
- 32. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware
- guantification of transcript expression. *Nature Methods* **14**, 417–419 (2017).
- 871 33. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification.
- 872 Nat Biotechnol **34**, 525–527 (2016).
- 873 34. Jaffe, A. E. et al. Developmental and genetic regulation of the human cortex transcriptome illuminate
- schizophrenia pathogenesis. *Nat Neurosci* **21**, 1117–1125 (2018).
- 875 35. Collado-Torres, L. et al. Regional Heterogeneity in Gene Expression, Regulation, and Coherence in
- the Frontal Cortex and Hippocampus across Development and Schizophrenia. Neuron 103, 203-
- 877 216.e8 (2019).
- 36. Jaffe, A. E. et al. Profiling gene expression in the human dentate gyrus granule cell layer reveals
- insights into schizophrenia and its genetic risk. Nat Neurosci 23, 510–519 (2020).
- 880 37. Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues.
- 881 Science **369**, 1318–1330 (2020).
- 38. Breiman, L. & Friedman, J. H. Predicting Multivariate Responses in Multiple Linear Regression.
- Journal of the Royal Statistical Society: Series B (Statistical Methodology) 59, 3–54 (1997).
- 39. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association studies.
- 885 Nature Genetics **48**, 245–252 (2016).
- 40. Gamazon, E. R. et al. A gene-based association method for mapping traits using reference
- transcriptome data. *Nature Genetics* **47**, 1091–1098 (2015).
- 41. Love, M. I. et al. Tximeta: Reference sequence checksums for provenance identification in RNA-seq.
- 889 PLOS Computational Biology **16**, e1007664 (2020).
- 42. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level
- 891 estimates improve gene-level inferences. *F1000Research 2015 4:1521* **4**, 1521 (2016).

- 43. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via
- 893 Coordinate Descent. *Journal of Statistical Software* **33**, 1–22 (2010).
- 44. Rothman, A. J., Levina, E. & Zhu, J. Sparse multivariate regression with covariance estimation.
- Journal of Computational and Graphical Statistics 19, 947–962 (2010).
- 45. Rauschenberger, A. & Glaab, E. Predicting correlated outcomes from molecular data. *Bioinformatics*
- **37**, 3889–3895 (2021).
- 46. Chun, H. & Keleş, S. Sparse partial least squares regression for simultaneous dimension reduction
- and variable selection. J R Stat Soc Series B Stat Methodol 72, 3–25 (2010).
- 900 47. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in
- 901 regression, with application to genetic fine mapping. Journal of the Royal Statistical Society: Series B
- 902 **82**, 1273–1300 (2020).
- 903 48. Endelman, J. B. Ridge Regression and Other Kernels for Genomic Selection with R Package rrBLUP.
- 904 The Plant Genome **4**, 250–255 (2011).
- 905 49. Liu, Y. et al. ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in
- 906 Sequencing Studies. *Am J Hum Genet* **104**, 410–421 (2019).
- 907 50. Van den Berge, K., Soneson, C., Robinson, M. D. & Clement, L. stageR: a general stage-wise
- method for controlling the gene-level false discovery rate in differential expression and differential
- 909 transcript usage. *Genome Biology 2017 18:1* **18**, 1–14 (2017).
- 910 51. Auton, A. et al. A global reference for human genetic variation. Nature vol. 526 68–74 Preprint at
- 911 https://doi.org/10.1038/nature15393 (2015).
- 912 52. Cao, C. et al. Power analysis of transcriptome-wide association study: Implications for practical
- 913 protocol choice. *PLoS Genetics* **17**, e1009405–e1009405 (2021).
- 914 53. Cao, C. et al. Power analysis of transcriptome-wide association study: Implications for practical
- 915 protocol choice. *PLoS Genetics* **17**, e1009405 (2021).
- 916 54. Vitting-Seerup, K. & Sandelin, A. IsoformSwitchAnalyzeR: analysis of changes in genome-wide
- patterns of alternative splicing and its functional consequences. *Bioinformatics* **35**, 4469–4471
- 918 (2019).

- 919 55. Mancuso, N. et al. Probabilistic fine-mapping of transcriptome-wide association studies. Nature
- 920 Genetics **51**, 675–682 (2019).
- 921 56. Vialle, R. A., de Paiva Lopes, K., Bennett, D. A., Crary, J. F. & Raj, T. Integrating whole-genome
- 922 sequencing with multi-omic data reveals the impact of structural variants on gene regulation in the
- 923 human brain. *Nat Neurosci* **25**, 504–514 (2022).
- 924 57. RL, W. et al. Genetic Control of Expression and Splicing in Developing Human Brain Informs Disease
- 925 Mechanisms. *Cell* **179**, 750-771.e22 (2019).
- 926 58. Grove, J. et al. Identification of common genetic risk variants for autism spectrum disorder. Nature
- 927 genetics **51**, 431–444 (2019).
- 928 59. Demontis, D. et al. Discovery of the first genome-wide significant risk loci for attention
- deficit/hyperactivity disorder. *Nature Genetics* **51**, 63–75 (2019).
- 930 60. Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways
- 931 influencing Alzheimer's disease risk. Nature Genetics 51, 404–413 (2019).
- 932 61. Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder cases
- provides new insights into the underlying biology. *Nat Genet* **53**, 817–829 (2021).
- 934 62. Jansen, P. R. et al. Genome-wide meta-analysis of brain volume identifies genomic loci and genes
- 935 shared with intelligence. *Nat Commun* **11**, 5606 (2020).
- 936 63. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders.
- 937 *Cell* **179**, 1469-1482.e11 (2019).
- 938 64. Grasby, K. L. et al. The genetic architecture of the human cerebral cortex. Science **367**, eaay6690
- 939 (2020).
- 65. Adams, H. H. et al. Novel genetic loci underlying human intracranial volume identified through
- genome-wide association. *Nat Neurosci* **19**, 1569–1582 (2016).
- 66. Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent variants
- 943 and highlights the importance of the prefrontal brain regions. *Nature Neuroscience* **22**, 343–352
- 944 (2019).
- 945 67. Nagel, M. et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484
- 946 individuals identifies novel genetic loci and pathways. *Nat Genet* **50**, 920–927 (2018).

- 947 68. Arnold, P. D. et al. Revealing the complex genetic architecture of obsessive-compulsive disorder
- 948 using meta-analysis. *Molecular Psychiatry* **23**, 1181–1188 (2018).
- 949 69. Forstner, A. J. et al. Genome-wide association study of panic disorder reveals genetic overlap with
- neuroticism and depression. *Mol Psychiatry* **26**, 4179–4190 (2021).
- 951 70. Nievergelt, C. M. et al. International meta-analysis of PTSD genome-wide association studies
- 952 identifies sex- and ancestry-specific genetic risk loci. Nat Commun 10, 4558 (2019).
- 953 71. Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia.
- 954 Nature **604**, 502–508 (2022).
- 955 72. Watson, H. J. et al. Genome-wide association study identifies eight risk loci and implicates metabo-
- 956 psychiatric origins for anorexia nervosa. *Nat Genet* **51**, 1207–1214 (2019).
- 957 73. Prive, F., Aschard, H., Ziyatdinov, A. & Blum, M. G. B. Efficient analysis of large-scale genome-wide
- data with two R packages: Bigstatsr and bigsnpr. *Bioinformatics* **34**, 2781–2787 (2018).
- 959 74. Consortium, T. S. W. G. of the P. G., Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic
- loci prioritises genes and implicates synaptic biology in schizophrenia. 2020.09.12.20192922 Preprint
- 961 at https://doi.org/10.1101/2020.09.12.20192922 (2020).
- 962 75. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291
- 963 (2016).
- 76. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456
- 965 humans. *Nature* **581**, 434–443 (2020).
- 77. Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat Genet **50**, 151–158
- 967 (2018).
- 78. Du, P. et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by
- microarray analysis. *BMC Bioinformatics* **11**, 587–587 (2010).
- 79. van Iterson, M., van Zwet, E. W., Heijmans, B. T. & Heijmans, B. T. Controlling bias and inflation in
- 971 epigenome- and transcriptome-wide association studies using the empirical null distribution. Genome
- 972 Biology **18**, 19–19 (2017).
- 973 80. Schrode, N. et al. Synergistic effects of common schizophrenia risk variants. Nat Genet 51, 1475-
- 974 1485 (2019).

- 975 81. Bhattacharjee, S. et al. A Subset-Based Approach Improves Power and Interpretation for the
- 976 Combined Analysis of Genetic Association Studies of Heterogeneous Traits. Am J Hum Genet 90,
- 977 821–835 (2012).
- 978 82. O'Donnell-Luria, A. H. et al. Heterozygous Variants in KMT2E Cause a Spectrum of
- 979 Neurodevelopmental Disorders and Epilepsy. Am J Hum Genet **104**, 1210–1222 (2019).
- 980 83. Reay, W. R. & Cairns, M. J. Pairwise common variant meta-analyses of schizophrenia with other
- 981 psychiatric disorders reveals shared and distinct gene and gene-set associations. *Transl Psychiatry*
- 982 **10**, 1–11 (2020).
- 983 84. Nishioka, K. et al. PR-Set7 Is a Nucleosome-Specific Methyltransferase that Modifies Lysine 20 of
- 984 Histone H4 and Is Associated with Silent Chromatin. *Molecular Cell* **9**, 1201–1213 (2002).
- 985 85. Schmidt-Kastner, R., Guloksuz, S., Kietzmann, T., van Os, J. & Rutten, B. P. F. Analysis of GWAS-
- Derived Schizophrenia Genes for Links to Ischemia-Hypoxia Response of the Brain. Front Psychiatry
- 987 **11**, 393 (2020).
- 988 86. Wong, H. et al. Isoform-specific roles for AKT in affective behavior, spatial memory, and extinction
- related to psychiatric disorders. *eLife* **9**, e56630 (2020).
- 990 87. Howell, K. R., Floyd, K. & Law, A. J. PKBγ/AKT3 loss-of-function causes learning and memory
- 991 deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia. *PLoS One* **12**,
- 992 e0175993 (2017).
- 993 88. Chen, H.-Y. & Maher, B. J. Lost in Translation: Cul3-Dependent Pathological Mechanisms in
- 994 Psychiatric Disorders. *Neuron* **105**, 398–399 (2020).
- 995 89. Pouget, J. G. The Emerging Immunogenetic Architecture of Schizophrenia. Schizophrenia Bulletin
- 996 **44**, 993–1004 (2018).
- 997 90. Liu, D. et al. Rare schizophrenia risk variant burden is conserved in diverse human populations.
- 998 2022.01.03.22268662 Preprint at https://doi.org/10.1101/2022.01.03.22268662 (2022).
- 999 91. The GIT Family of Proteins Forms Multimers and Associates with the Presynaptic Cytomatrix Protein
- 1000 Piccolo* Journal of Biological Chemistry. https://www.jbc.org/article/S0021-9258(20)86625-3/fulltext.
- 92. Bhattacharya, A. isoTWAS models using 48 GTEx tissues and PsychENCODE data (07.04.22).
- 1002 (2022) doi:10.5281/zenodo.6795947.

- 93. Qi, T. et al. Genetic control of RNA splicing and its distinct role in complex trait variation. Nat Genet
- 1004 (2022) doi:10.1038/s41588-022-01154-4.
- 1005 94. Delaneau, O. et al. A complete tool set for molecular QTL discovery and analysis. Nature
- 1006 *Communications* **8**, (2017).
- 1007 95. Schwarz, T. et al. Powerful eQTL mapping through low coverage RNA sequencing.
- 1008 2021.08.08.455466 Preprint at https://doi.org/10.1101/2021.08.08.455466 (2021).
- 1009 96. Doose, G., Bernhart, S. H., Wagener, R. & Hoffmann, S. DIEGO: detection of differential alternative
- splicing using Aitchison's geometry. *Bioinformatics* **34**, 1066–1068 (2018).
- 1011 97. Veturi, Y. & Ritchie, M. D. How powerful are summary-based methods for identifying expression-trait
- associations under different genetic architectures? in *Pacific Symposium on Biocomputing* vol. 0
- 1013 228–239 (World Scientific Publishing Co. Pte Ltd, 2018).
- 98. Bhattacharya, A. et al. Best practices for multi-ancestry, meta-analytic transcriptome-wide association
- studies: lessons from the Global Biobank Meta-analysis Initiative. medRxiv 3, 2021.11.24.21266825-
- 1016 2021.11.24.21266825 (2021).
- 1017 99. Zhu, A. et al. MRLocus: Identifying causal genes mediating a trait through Bayesian estimation of
- allelic heterogeneity. *PLOS Genetics* **17**, e1009455–e1009455 (2021).
- 1019 100. Whalen, S., Schreiber, J., Noble, W. S. & Pollard, K. S. Navigating the pitfalls of applying
- machine learning in genomics. *Nat Rev Genet* **23**, 169–181 (2022).
- 1021 101. Endelman, J. B. Ridge Regression and Other Kernels for Genomic Selection with R Package
- 1022 rrBLUP. The Plant Genome **4**, 250–255 (2011).
- 1023 102. Van den Berge, K., Soneson, C., Robinson, M. D. & Clement, L. stageR: a general stage-wise
- method for controlling the gene-level false discovery rate in differential expression and differential
- transcript usage. *Genome Biology 2017 18:1* **18**, 1–14 (2017).
- 1026 103. Wang, X., Lu, Z., Bhattacharya, A., Pasaniuc, B. & Mancuso, N. twas_sim, a Python-based tool
- for simulation and power analysis of transcriptome-wide association analysis. *Bioinformatics* **39**,
- 1028 btad288 (2023).
- 1029 104. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and
- microarray studies. *Nucleic Acids Research* **43**, e47–e47 (2015).

- 1031 105. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-
- seq data with DESeq2. *Genome Biology* **15**, 550–550 (2014).
- 1033 106. Zhu, A., Srivastava, A., Ibrahim, J. G., Patro, R. & Love, M. I. Nonparametric expression analysis
- using inferential replicate counts. *Nucleic Acids Research* **47**, e105 (2019).
- 1035 107. Kowalski, M. H. et al. Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed)
- 1036 Consortium whole genome sequences improves imputation quality and detection of rare variant
- associations in admixed African and Hispanic/Latino populations. *PLoS Genetics* **15**, e1008500–
- 1038 e1008500 (2019).
- 1039 108. Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel.
- 1040 Nature Genetics 48, 1443–1448 (2016).
- 1041 109. Zhao, H. et al. CrossMap: a versatile tool for coordinate conversion between genome assemblies.
- 1042 Bioinformatics **30**, 1006–1007 (2014).
- 1043 110. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based
- 1044 Linkage Analyses. *Am. J. Hum. Genet* **81**, 559–575 (2007).
- 1045 111. Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
- 1046 Nature **590**, 290–299 (2021).
- 1047 112. Das, S. et al. Next-generation genotype imputation service and methods. Nature Genetics 48,
- 1048 1284–1287 (2016).
- 1049 113. Belmont, J. W. et al. The international HapMap project. Nature 426, 789–796 (2003).
- 1050 114. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079
- 1051 (2009).
- 1052 115. Love, M. I. et al. Tximeta: Reference sequence checksums for provenance identification in RNA-
- seq. PLOS Computational Biology **16**, e1007664–e1007664 (2020).
- 1054 116. WGCNA: an R package for weighted correlation network analysis | BMC Bioinformatics | Full
- Text. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-9-559.
- 1056 117. Leek, J. T. & Storey, J. D. Capturing Heterogeneity in Gene Expression Studies by Surrogate
- 1057 Variable Analysis. *PLoS Genetics* **3**, e161–e161 (2007).

118. Mostafavi, S. et al. Normalizing RNA-Sequencing Data by Modeling Hidden Covariates with Prior 1058 1059 Knowledge. PLoS ONE 8, e68141-e68141 (2013). 1060 119. Picard toolkit. (2018). 1061 120. Delaneau, O. et al. A complete tool set for molecular QTL discovery and analysis. Nature 1062 Communications 8, (2017). 121. Zhang, W. et al. Integrative transcriptome imputation reveals tissue-specific and shared biological 1063 mechanisms mediating susceptibility to complex traits. Nature Communications 10, 3834–3834 1064 1065 (2019).1066 122. Bhattacharya, A. isoTWAS models for 48 GTEx models (06/2023). (2023) 1067 doi:10.5281/zenodo.8047940. 123. Bhattacharya, A. isoTWAS models for adult brain cortex (06/2023). (2023) 1068 doi:10.5281/zenodo.8048198. 1069 1070 124. Bhattacharya, A. isoTWAS models for developmental brain cortex (06/2023). (2023) 1071 doi:10.5281/zenodo.8048137. 1072 1073 **FIGURE LEGENDS** 1074 1075 Figure 1: Isoform-centric approach for complex trait mapping and prioritization of disease mechanisms at 1076 a genetic locus. (a) Motivation for isoTWAS. Gene G has three isoforms associated with a trait but only one has an effect on the trait. Gene G itself does not show an association with the trait. Studying genetic 1077 associations with an isoform-centric perspective will prioritize Gene G, but not with a gene-centric 1078 1079 perspective. (b) Schematic comparison of isoTWAS and TWAS. First, isoTWAS differs from TWAS by 1080 training a multivariate model of isoform expression, while TWAS models total gene expression, the sum of 1081 isoform expression. Second, isoTWAS maps isoform-trait associations through a step-wise hypothesis testing framework that provides gene-level false discovery control and isoform-level family-wide error rate 1082 control. TWAS only maps gene-trait association. 1083 1084

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

Figure 2: IsoTWAS models predict gene expression with more accuracy than TWAS models in simulated data. (a) Simulation setup to generate isoform expression with specified isoQTL architecture, controlled expression heritability, number of isoforms, and inter-isoform correlation structure. (b) Proportion of simulations where the isoTWAS model has the maximum adjusted R² for marginal isoform prediction (Yaxis) across shared isoQTL proportion (X-axis), colored by isoTWAS method, facetted by causal isoQTL proportion (top margin) and proportion of isoform expression variance attributed to shared non cis-genetic effects (right margin). (c) Boxplots of difference in adjusted R² in predicting gene expression between isoTWAS and TWAS models from simulations with sample size 500 where isoform and gene expression heritability are set to 0.05, across causal isoQTL proportion (X-axis) and colored by number of transcripts per gene, facetted by proportion of shared isoQTLs (top margin) and proportion of variance explained by shared non cis-genetic effects (right margin). Figure 3: Multivariate isoform-level predictive models improve upon gene-level predictive models in predictive gene-level expression. (a) Barplot showing the number of isoforms with CV R² > 0.01 (Y-axis) using multivariate (cream) and univariate (blue) modelling methods across brain tissues (X-axis). (b) Boxplot of median percent difference in predicting isoform expression (Y-axis) using multivariate compared to univariate method by brain and other tissue (X-axis). P-value corresponds to difference in median across groups, adjusted for sample size. (c) Barplot showing the number of genes passing CV thresholds (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues. (d) Barplot showing the number of genes with CV R² > 0.01 (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues (X-axis). (e) Boxplot of percent difference in R² (Y-axis) of predicting gene expression (isoTWAS – TWAS) in external datasets. X-axis shows the training and imputation datasets. The median percent difference in labelled. Figure 4: IsoTWAS improves power to detect gene-trait associations, especially when genetic effects differ across isoforms, in simulations. (a) Power to detect gene-trait association (proportion of tests with P < 2.5 x 10⁻⁶, Y-axis) across causal proportion of isoQTLs (X-axis), facetted by proportion of shared isoQTLs (top margin) and proportion of variance explained by shared non cis-genetic effects (right

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

margin). (b) Power to detect gene-trait association (proportion of tests with P < 2.5 x 10⁻⁶, Y-axis) across proportion of gene expression explained by effect isoform (X-axis). (c) Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across ratio of effect sizes for 2 effect isoforms. Across all plots, isoform and total gene expression heritability is set to 0.05 and causal proportion of 0.01 in (b-c). Points are colored by method and shaped by the number of isoforms per gene. Figure 5: Isoform-level trait mapping increases discovery of genetic associations over gene-level trait mapping. (a) Schematic diagram for trait mapping using gene-level TWAS and isoTWAS using PsychENCODE data. (b) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb using gene-level TWAS (red), isoTWAS (blue), or either (green) at conservative permutation-based significance thresholds. (c) Scatterplot of standardized effect sizes (Z-scores) using isoTWAS and genelevel TWAS, considered associations with nominal P < 0.05 using both TWAS and isoTWAS. Gray line shows the 45-degree line and the green line shows an ordinary least squares regression. (d) Empirical Bayes estimate of test statistic inflation (X-axis) for TWAS (red) and isoTWAS (red) gene-level associations across 15 traits (Y-axis). (e) Mean percent increase in approximate χ^2 -test statistic (squared Z-score), which is proportional to increase in effective sample size, for isoTWAS trait associations over TWAS trait associations. (f) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb using splicing-event-based TWAS (purple), isoTWAS (blue), or either (green) at conservative permutation-based significance thresholds. Figure 6: isoTWAS implicates isoforms of AKT3, CUL3, HSPD1, and PCL0 in genetic associations with psychiatric traits. In each plot, (top) Manhattan plots of GWAS risk, total gene eQTLs, and isoQTLs, colored by LD to the lead isoQTL and lead isoQTL shown in a triangle and labelled. LD is based on the 1000 Genomes European reference. (bottom) Boxplots of gene and isoform expression by genotype of the lead isoQTL SNP and forest plot of the lead isoQTL's effect and 95% confidence interval on the trait, gene, and isoform, with P-values labelled. (a) SCZ risk, AKT3 gene expression, and ENST00000492957 isoform expression. (b) SCZ risk, CUL3 gene expression, ENST00000409096 isoform expression. (c)

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

SCZ risk, HSPD1 gene expression, ENST00000678969 isoform expression. (d) CDG risk, PCLO gene expression, ENST00000423517 isoform expression. SUPPLEMENTAL INFORMATION **Supplemental Methods** Supplemental Methods are provided in the attached Supplemental Methods.pdf. **Supplemental Figure Legends** Figure S1: Directed acyclic graph (DAG) illustrating causal assumptions in isoTWAS. We assume that the local genetic variants within 1 Megabase of a gene have direct effects on the expression of a gene G and its isoforms; these genetic effects need not be shared across isoforms and the gene. Furthermore, we assume that the abundance of a gene is the sum of abundances of its isoforms. Lastly, we assume that the isoform and gene need not affect the complex trait through the same path. We also acknowledge that genetic variants may have effects on the trait through pathways independent of gene and isoform expression. Figure S2: Step-wise hypothesis testing in isoTWAS. First, isoform-trait associations are estimated either using appropriate regressions of imputed expression in individual-level GWAS or the weighted burden test in Gusev et al in GWAS summary statistics. Then, associations for isoforms of the same gene are aggregated to the gene-level using the Aggregated Cauchy Association Test (ACAT). These aggregated gene-level associations are adjusted for multiple testing burden to control the false discovery rate (FDR) using either a Bonferroni or Benjamini-Hochberg procedure. Lastly, for isoforms of genes that pass genelevel testing, we control the family-wide error rate (FWER) using Shaffer's modified sequentially rejective procedure. Figure S3: Comparison of predictive performance of 6 models implemented in isoTWAS. Across 1,000 simulations of 5 isoforms with isoform heritability (h_i^2) set to 0.05 or 0.10. Boxplots of adjusted R² of prediction of isoform expression (Y-axis) across shared isoQTL proportion (X-axis)

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

Figure \$4: IsoTWAS models predict gene expression with more accuracy than TWAS models. Boxplots of percent difference in adjusted R² in predicting gene expression between isoTWAS and TWAS models from simulations with sample size 200 (compare with sample size 500 in Figure 2), where isoform and gene expression heritability are set to (top) 0.05 and (bottom) 0.10. Figure S5: Across 48 GTEx tissues (Y-axis), the number of multivariate (cream) and univariate (blue) models predicting isoform expression at CV R² > 0.01 (X-axis). Figure S6: Across 48 GTEx tissues (Y-axis), percent difference in CV R2 (X-axis) of prediction of isoform expression models using multivariate models versus univariate models. The label shows the proportion of isoforms with improved performance using multivariate models. Figure S7: Number of isoforms with CV R² > 0.01 (Y-axis) using the baseline univariate model (teal, best univariate) and 4 multivariate models. Figure \$8: Across 48 GTEx tissues (Y-axis), number of genes that pass TWAS (blue) and isoTWAS (red) CV R² cutoffs to be available for testing in the trait-mapping step (X-axis) Figure S9: Across 48 GTEx tissues (Y-axis), percent difference in CV R2 (X-axis) of prediction of isoform expression models using multivariate models versus univariate models. The label shows the proportion of isoforms with improved performance using multivariate models. Figure \$10: Across 48 GTEx tissues (Y-axis), number of genes predicted at CV R² > 0.01 using TWAS (blue) and isoTWAS (red) Figure S11: Number of genes (left) and isoforms (right) predicted at CV R² > 0.01 using isoTWAS across 48 GTEx tissues.

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

Figure \$12: Performance of isoTWAS across number of isoforms per gene across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at R² > 0.01 using multivariate versus univariate prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Median number of isoforms predicted at CV R² > 0.01 in isoTWAS models across increasing number of isoforms per gene. The red line shows the line Y = X + 1. (d) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS. Figure \$13: Performance of isoTWAS across increasing maximum isoform fraction across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at R² > 0.01 using multivariate versus univariate prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS. Figure S14: Performance of isoTWAS across increasing gene length across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with CV R² > 0.01 using isoTWAS versus TWAS. R² > 0.01 using isoTWAS versus TWAS. Figure \$15: Performance of isoTWAS across increasing SNP density across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS. Figure \$16: Performance of isoTWAS across increasing sample size across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS.

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

Figure \$17: Performance of isoTWAS across proportion of shared isoTWAS model effect SNPs across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at R² > 0.01 using multivariate versus univariate prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS. Figure \$18: Performance of isoTWAS across increasing mean counts of isoforms and genes across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at R² > 0.01 using multivariate versus univariate prediction across increasing mean counts of isoforms. (b) Ratio of number of genes with CV R² > 0.01 using isoTWAS versus TWAS across increasing mean counts of genes. Figure \$19: Performance of isoTWAS across increasing quantification variance of isoforms and genes across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at R² > 0.01 using multivariate versus univariate prediction across increasing quantification variance of isoforms. (b) Ratio of number of genes with CV R² > 0.01 using isoTWAS versus TWAS across increasing quantification variance of genes. Figure S20: (a) Median percent difference in R2 of predicting original isoform expression using multivariate versus univariate models across increasing number of isoforms per gene, colored by models trained in the original dataset (pink) and the leave-one-out dataset (teal) (b) Median percent difference in R² of predicting original gene expression using isoTWAS versus TWAS models across increasing number of isoforms per gene, colored by models trained in the original dataset (pink) and the leave-one-out dataset (teal) Figure S21: IsoTWAS and gene-level TWAS show relatively similar false positive rates. Across 20 iterations of 1,000 simulations, boxplots of false positive rate to detect a gene-trait association using Cauchy-aggregated P-values of isoform-trait associations (red) and gene-level TWAS (blue). In these simulations, we simulate 200 and 5,000 samples in the eQTL and GWAS panels, 5 isoforms, and isoform and gene expression heritability of 0.10. We vary the causal isoQTLs proportion (pc, shown on X-axis), the QTL architecture (right margin), and correlation between isoforms (top margin). For each iteration, we

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

simulate one eQTL panel and 1,000 GWAS panels where genetically-regulated gene and isoform expression have no effect on the trait. We calculate the false positive rate as the proportion of the 1,000 tests that give P > 0.05. Figure S22: Power comparison between TWAS and isoTWAS in detecting gene-trait association across 3 scenarios (Methods). (a) Power to detect gene-trait association (proportion of tests with P < 2.5 x 10⁻⁶, Yaxis) across number of total isoforms per gene (X-axis), facetted by proportion of shared isoQTLs (top margin) and proportion of expression heritability attributed to shared non-genetic effects across isoforms (right margin). Points are shaped by causal isoQTL proportion and colored by method. (b) Power to detect gene-trait association (proportion of tests with P < 2.5 x 10⁻⁶, Y-axis) across proportion of gene expression explained by effect isoform (X-axis), facetted by proportion of shared isoQTLs (top margin) and proportion of expression heritability attributed to shared non-genetic effects across isoforms (right margin). Points are shaped by number of isoforms per gene and colored by method. (c) Power to detect gene-trait association (proportion of tests with P < 2.5 x 10⁻⁶, Y-axis) across ratio of effect sizes of 2 effect isoforms (X-axis), facetted by proportion of shared isoQTLs (top margin) and proportion of expression heritability attributed to shared non-genetic effects across isoforms (right margin). Points are shaped by number of isoforms per gene and colored by method. Here, expression heritability is set of 0.05, trait heritability is set to 0.1, and causal proportion of (b-c) is set of 0.01. Figure S23: Sensitivity (a) and mean set size (b) of 90% credible set using FOCUS to finemap isoformtrait associations for a single gene, across causal isoQTL proportion (X-axis). Points are colored by trait heritability and shaped by the number of isoforms per gene. Plots are facetted by proportion of shared isoQTLs (top margin) and proportion of expression heritability attributed to shared non-genetic effects across isoforms (right margin). Line-range shows a 95% jackknife confidence interval. Figure S24: Schematic diagram for analysis using adult and developmental frontal cortex data from PsychENCODE and AMP-AD. Data sources for eQTL reference data, GWAS cohorts, and reference LD

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

data are provided on the left (black). The full gene-level TWAS (red) and isoTWAS (blue) are summarized on the right. Figure S25: Number of gene-trait associations (Y-axis) using TWAS (red) and isoTWAS (blue) across trait (X-axis), faceting by tissue (top margin) and threshold (right margin: adjusted P < 0.05 and permutation P < 0.05, top; in 90% credible set using FOCUS fine-mapping, bottom). Figure S26: Number of isoform-trait associations (Y-axis) using isoTWAS across trait (X-axis), faceting by tissue (top margin) and threshold (right margin: adjusted P < 0.05 and permutation P < 0.05, top; in 90% credible set using FOCUS fine-mapping, bottom). Figure S27: QQ-plots of gene-level P-values using TWAS (red) and isoTWAS (blue) across 15 traits. Figure S28: (a) Distribution of number of genes in risk region (left) and in 90% credible set (right) using TWAS and isoTWAS. (b) Distribution of number of isoforms per gene in risk region (left) and in 90% credible set (right) using isoTWAS. Figure S29: Lollipop plot of enrichment ratio (X-axis) of ontologies (Y-axis) for isoTWAS-prioritized genes associated at adjusted P < 0.05 and permutation P < 0.05. Points are shaped by tissue type (adult or developmental) and colored by ontology type (biological process, cell component, molecular function). Figure \$30: For ENST00000681794 association with BV (a) and ENST00000492957 with BV (b), Manhattan plots of GWAS, eQTL, and isoQTL signal colored by LD (top), boxplots of gene (red) and isoform (blue) expression (Y-axis) by genotype (X-axis) (bottom left), and forest plot of lead isoQTL association with isoform (blue), gene (red), and trait (black) (bottom right). (c) Comparison of exon and intron structure of ENST00000681794 and ENST00000492957, based on Gencode v38 reference. **Supplemental Tables**

Table S1: Sample size, source, and tissues for functional genomics reference panels Table S2: Number of genes/models that pass cross-validation prediction cutoffs using TWAS and isoTWAS feature selection criteria and prediction methods Table S3: Distribution of predictive external R2 of observed total gene expression vs. predicted total gene expression (isoTWAS -TWAS) Table S4: Number of GWAS loci with an isoTWAS-, TWAS-, and splice-TWAS-prioritized gene within 0.5 Mb **Table S5**: TWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.05 across 15 traits using adult brain cortex models **Table S6**: isoTWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.05 across 15 traits using adult brain cortex models **Table S7**: TWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.05 across 15 traits using developmental brain cortex models **Table S8:** isoTWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.05 across 15 traits using developmental brain cortex models Table S9: Empirical bayes estimates of test statistic inflation and increase in χ² test statistics of genelevel associations using isoTWAS and TWAS Table S10: Accession numbers and URLs for data access

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

Supplemental Data Data 1: Predictive performance comparison of isoTWAS multivariate methods in simulated data across a variety of genetic architecture settings Data 2: Predictive performance comparison of isoTWAS and TWAS gene expression prediction in simulated data across a variety of genetic architecture settings Data 3: Isoform expression prediction metrics across a variety of factors, using 48 GTEx datasets Data 4: Gene expression prediction metrics across a variety of factors, using 48 GTEx datasets **Data 5**: False positive rates using isoTWAS and TWAS to detect a gene-trait association at P < 0.05 across a variety genetic architecture parameters **Data 6**: Power to detect trait association at P < 2.5 x 10⁻⁶ across 1,000 simulations each for 22 genes using TWAS and isoTWAS across various simulations. These simulations are under Scenario 1 in Figure 4a (gene has a true effect on the trait, but none of the isoforms have a true effect on the trait) **Data 7**: Power to detect trait association at P < 2.5 x 10⁻⁶ across 1,000 simulations each for 22 genes using TWAS and isoTWAS (ACAT) across various simulations. These simulations are under Scenario 2 in Figure 4b (a gene has multiple isoforms, only one has an effect on the trait, and we vary the usage of this effect isoform) **Data 8**: Power to detect trait association at P < 2.5 x 10⁻⁶ across 1,000 simulations each for 22 genes using TWAS and isoTWAS (ACAT) across various simulations. These simulations are under Scenario 3 in Figure 4c (a gene has two isoforms with differing effects on the trait, and we vary the effect size of one of the isoforms)

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

Data 9: Sensitivity and mean set size of 90% credible sets determined by FOCUS in simulated data across a variety of genetic architecture parameters Data 10: Raw TWAS results across 15 neuropsychiatric traits using adult brain cortex expression models Data 11: Raw isoTWAS results across 15 neuropsychiatric traits using adult brain cortex expression models Data 12: Raw TWAS results across 15 neuropsychiatric traits using developmental brain cortex expression models Data 13: Raw isoTWAS results across 5 neuropsychiatric traits using developmental brain cortex expression models Data 14: GWAS and nominal eQTL and isoQTL summary statistics corresponding to isoTWAS isoformtrait association examples shown in Figure 7 and Supplemental Figure S30. **ACKNOWLEDGEMENTS** We thank Kangcheng Hou, Tommer Schwarz, Vidhya Venkateswaran, Pan Zhang, Leanna Hernandez, Nathan LaPierre, Harold Pimentel, Mike Love, and Achal Patel for engaging discussion during the research process. We thank Kanishka Patel for her aesthetic advice for figures. We thank the Psychiatric Genomics Consortium and Complex Trait Genomics Lab for their publicly available GWAS summary statistics. BP was partially supported by NIH awards R01 HG009120, R01 MH115676, R01 CA251555, R01 AI153827, R01 HG006399, R01 CA244670, and U01 HG011715. MJG was supported by SFARI Bridge to Independence Award, NIMH R01-MH121521, NIMH R01-MH123922, and NICHD-P50-HD103557.

1391 1392 **AUTHOR INFORMATION Contributions** 1393 Conceptualization: AB, BP, MJG; Methodology: AB, BP, MJG; Software: AB; Validation: AB; Formal 1394 1395 analysis: AB, MK, CW, CJ; Investigation: AB, MJG; Resources: BP, MJG; Data curation: AB, MK, CW, CJ, MJG; Writing – original draft: AB, MJG; Writing – reviewing and editing: AB, MK, CW, CJ, BP, MJG; 1396 Visualization: AB; Supervision: BP, MJG; Project administration: BP, MJG; Funding acquisition: BP, MJG 1397 1398 1399 Correspondence 1400 Please direct all correspondence to Arjun Bhattacharya (abtbhatt@ucla.edu). 1401 **ETHICS DECLARATIONS** 1402 1403 **Competing Interests** 1404 The authors declare no competing interests.




Figure 1: Isoform-centric approach for complex trait mapping and prioritization of disease mechanisms at a genetic locus. (a) Motivation for isoTWAS. Gene G has three isoforms associated with a trait but only one has an effect on the trait. Gene G itself does not show an association with the trait. Studying genetic associations with an isoform-centric perspective will prioritize Gene G, but not with a gene-centric perspective. (b) Schematic comparison of isoTWAS and TWAS. First, isoTWAS differs from TWAS by training a multivariate model of isoform expression, while TWAS models total gene expression, the sum of isoform expression. Second, isoTWAS maps isoform-trait associations through a step-wise hypothesis testing framework that provides gene-level false discovery control and isoform-level family-wide error rate control. TWAS only maps gene-trait association.




Figure 2: *IsoTWAS models predict gene expression with more accuracy than TWAS models in simulated data.* **(a)** Simulation setup to generate isoform expression with specified isoQTL architecture, controlled expression heritability, number of isoforms, and inter-isoform correlation structure. **(b)** Proportion of simulations where the isoTWAS model has the maximum adjusted R² for marginal isoform prediction (Y-axis) across shared isoQTL proportion (X-axis), colored by isoTWAS method, facetted by causal isoQTL proportion (top margin) and proportion of isoform expression variance attributed to shared non cis-genetic effects (right margin). **(c)** Boxplots of difference in adjusted R² in predicting gene expression between isoTWAS and TWAS models from simulations with sample size 500 where isoform and gene expression heritability are set to 0.05, across causal isoQTL proportion (X-axis) and colored by number of transcripts per gene, facetted by proportion of shared isoQTLs (top margin) and proportion of variance explained by shared non cis-genetic effects (right margin).




Figure 3: *Multivariate isoform-level predictive models improve upon gene-level predictive models in predictive gene-level expression.* **(a)** Barplot showing the number of isoforms with CV $R^2 > 0.01$ (Y-axis) using multivariate (cream) and univariate (blue) modelling methods across brain tissues (X-axis). **(b)** Boxplot of median percent difference in predicting isoform expression (Y-axis) using multivariate compared to univariate method by brain and other tissue (X-axis). P-value corresponds to difference in median across groups, adjusted for sample size. **(c)** Barplot showing the number of genes passing CV thresholds (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues. **(d)** Barplot showing the number of genes with CV $R^2 > 0.01$ (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues (X-axis). **(e)** Boxplot of percent difference in R^2 (Y-axis) of predicting gene expression (isoTWAS – TWAS) in external datasets. X-axis shows the training and imputation datasets. The median percent difference in labelled.




Figure 4: *IsoTWAS improves power to detect gene-trait associations, especially when genetic effects differ across isoforms, in simulations.* **(a)** Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^6$, Y-axis) across causal proportion of isoQTLs (X-axis), facetted by proportion of shared isoQTLs (top margin) and proportion of variance explained by shared non cis-genetic effects (right margin). **(b)** Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across proportion of gene expression explained by effect isoform (X-axis). **(c)** Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across ratio of effect sizes for 2 effect isoforms. Across all plots, isoform and total gene expression heritability is set to 0.05 and causal proportion of 0.01 in **(b-c)**. Points are colored by method and shaped by the number of isoforms per gene.




Figure 5: Isoform-level trait mapping increases discovery of genetic associations over gene-level trait mapping. (a) Schematic diagram for trait mapping using gene-level TWAS and isoTWAS using PsychENCODE data. (b) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb using gene-level TWAS (red), isoTWAS (blue), or either (green) at conservative permutation-based significance thresholds. (c) Scatterplot of standardized effect sizes (Z-scores) using isoTWAS and gene-level TWAS, considered associations with nominal P < 0.05 using both TWAS and isoTWAS. Gray line shows the 45-degree line and the green line shows an ordinary least squares regression. (d) Empirical Bayes estimate of test statistic inflation (X-axis) for TWAS (red) and isoTWAS (red) gene-level associations across 15 traits (Y-axis). (e) Mean percent increase in approximate χ^2 -test statistic (squared Z-score), which is proportional to increase in effective sample size, for isoTWAS trait associations over TWAS trait associations. (f) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb using splicing-event-based TWAS (purple), isoTWAS (blue), or either (green) at conservative permutation-based significance thresholds.




Figure 6: *isoTWAS implicates isoforms of AKT3, CUL3, HSPD1, and PCLO in genetic associations with psychiatric traits.* In each plot, (top) Manhattan plots of GWAS risk, total gene eQTLs, and isoQTLs, colored by LD to the lead isoQTL and lead isoQTL shown in a triangle and labelled. LD is based on the 1000 Genomes European reference. (bottom) Boxplots of gene and isoform expression by genotype of the lead isoQTL SNP and forest plot of the lead isoQTL's effect and 95% confidence interval on the trait, gene, and isoform, with P-values labelled. **(a)** SCZ risk, *AKT3* gene expression, and ENST00000492957 isoform expression. **(b)** SCZ risk, *CUL3* gene expression, ENST00000678969 isoform expression. **(d)** CDG risk, *PCLO* gene expression, ENST00000423517 isoform expression.